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ABSTRACT
Antibodies specific for DEC205, a dendritic cell (DC) endocytic receptor
that traffics to the antigen presentation pathway, have been shown to be
excellent tools for raising robust, sustained immune responses to co-delivered
vaccine antigens; however, strong immune responses are only elicited with the
aid of non-specific dendritic cell maturation factors, without which a tolerogenic
immune response is induced. We hypothesize that regulatory T cell epitopes
(Tregitopes) located in the αDEC205 sequence promotes tolerance, requiring
the use of non-specific immuno-stimulators to promote pro-inflammatory
immune responses. This hypothesis is based on previous research performed
by De Groot et al. 2008 who characterized a set of natural regulatory T cell
epitopes derived from human immunoglobulins (IgG) that were found to induce
tolerance by stimulating regulatory T cells (CD4+CD25+FoxP3+).
We believe that αDEC205 can be rendered less tolerogenic by modifying
its regulatory T cell epitope content and improve its capacity to induce
inflammatory responses without the aid of non-specific maturation factors to
activate the immune system.
In this work, the αDEC205 sequence was computationally screened for
putative HLA-Class II-restricted, regulatory T cell epitopes as targets for
elimination by mutation. Mutations affecting key amino acid sites, relevant to
peptide-HLA-DRB1*0401 binding, were carried out to reduce epitope binding
affinity to the HLA-DRB1*0401 allele. Sequence modifications confirmed to

disrupt peptide-HLA binding were incorporated into an array of
αDEC205:OVA-ORG (original sequence) variants (mutant sequences) via site
directed mutagenesis. Protein was produced by CHO-S cell transient
transfection. Purified variant αDEC205:OVA-ORG recombinant proteins were
utilized in DR4 in vivo immunizations and functional assays to observe T cell
activation and proliferative immune responses.
The αDEC205:OVA variants (HC54-MOD1, VH77-MOD1 & VH77MOD2) were shown to target and bind to dendritic cells as effectively as the
non-modified αDEC205:OVA antibody. Splenocytes were re-stimulated with
ovalbumin in the T cell proliferation assay and with OVA Class I (257-264) and
OVA Class II (323-339) peptides in the ELISpot assay to measure the memory
responses. Both αDEC205:OVA-VH77-MOD1 and αDEC205:OVA-VH77MOD2 showed statistically significant differences in CD8+ and CD4+ T cell
proliferation in comparison to splenocytes previously immunized with the
αDEC205:OVA-ORG antibody condition, respectively. However, a lack of
statistically significant IFN-γ cytokine production was observed for all variant
antibody immunization conditions. Further analyses are required to determine
the true significance observed from the αDEC205:OVA-VH77-MOD1 data set
as evidenced by the possible outliers, which may be skewing the results. The
αDEC205:OVA-HC54-MOD1 sequence failed to generate elevated levels of T
cell proliferation and IFN-γ secretion responses.
It was concluded that the αDEC205:OVA antibodies (VH77-MOD1 and
VH77-MOD2) induced statistically significant elevated T cell proliferative

responses in comparison to the baseline immune response levels of the nonmodified αDEC205:OVA-ORG antibody, suggesting that an improved vaccine
delivery system is underway due to the epitope modifications at the VH77
Tregitope sequence, which potentially decreased the tolerogenicity of the
αDEC-205:OVA antibody. In regards to the other variant antibodies, further
modifications to the Tregitope sequences in the αDEC205:OVA antibody’s
overall sequence may be necessary to reduce tolerogenicity further to begin to
create a detolerized antibody capable of inducing a pro-inflammatory immune
response without the aid of a non-specific immuno-stimulator.
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CHAPTER 1

INTRODUCTION

Since their discovery in 1973, dendritic cells (DCs) have proven to be
specialized immune cells and potent stimulators of primary immune responses
(Hart, 1997, Janeway et al. 2001, Granucci et al. 2005, Lipscomb et al. 2002).
Initial interest peaked when these bone marrow-derived cells were found to be
not only in mice, but also in most human lymphoid (spleen, thymus, and lymph
nodes) and non-lymphoid tissue (Hart, 1997, Lipscomb et al. 2002).
Information regarding DCs has only continued to grow, leading to the
knowledge that DCs play a central role in the immune system by controlling
both immune tolerance and immunity (Palucka et al. 2002, Granucci et al.
2005, Ueno et al. 2007, Steinman et al. 2006). Because of these qualities,
researchers are considering DCs as viable candidates to contribute to the
improvement of targeted vaccine delivery platform systems (Palucka et al.
2002, Hart, 1997, Tacken et al. 2007).
Myeloid lineage DCs originate from bone marrow and are a part of a
specific sub-population of cells (professional antigen presenting cells) (APCs),
which comprise both Macrophages and B cells (Chaterjee et al. 2012, Hart,
1997, Nagl et al. 1997, Steinman et al. 2006). A primary function of DCs is to
alert the immune system to any invading organism they may potentially
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encounter (Janeway et al. 2001). Thus, APCs’ antigen uptake process is an
essential and critical function of the immune system (Steinman et al. 2006,
Hart, 1997, Lipscomb et al. 2002). These cells efficiently process antigen, and
present it in peptide-form in context of up-regulated MHC complexes (Hart,
1997, Steinman et al. 2006, Steinman et al. 2000, Janeway et al. 2001).
Antigen-uptake facilitates directed antigen-specific T cell mediated immune
responses, leading to the initiation of an adaptive immune response, a more
specific and targeted immune response (Steinman et al. 2000, Hart, 1997,
Janeway et al. 2001, Male et al. 2006, Wilson et al. 2004, Tacken et al. 2007,
Bonifaz et al. 2002).
In order for DCs to perform this task, immature DCs circulate along the
tissue periphery, efficiently and continuously sampling their environment for
antigen in a variety of manners: phagocytosis of particles, fluid phase
macropinocytosis, receptor-mediated endocytosis, or direct contact with
apoptotic or infected cells (Nagl et al. 1997, Steinman et al. 2006, Hart, 1997).
Following the antigenic encounter, peripheral-immature DCs process and
present the antigen in peptide-form on DCs surfaces. Immature DCs express a
variety of CLRs that are down regulated after maturation (Tel et al. 2011).
Immature DCs then travel from the tissue periphery via the lymphatic
system to the nearest draining-lymph node, a secondary lymphoid organ, only
after receiving appropriate direct-pathogenic signals or environmental
inflammatory stimuli, causing the up-regulation of cell surface-chemokine
receptors and subsequent DC migration (Hart, 1997, Nagl et al. 1997). Within
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lymph nodes, the site of antigen localization, naive T cells are exposed to
antigenic peptides by mature DCs. Mature DCs then acquire the ability to
activate and facilitate naïve T cell polarization; a hallmark of mature DCs,
resulting in an antigen-specific T cell mediated immune response (Steinman et
al. 2000, Hart, 1997, Tel et al. 2011).
Since DCs can play a role in both innate and adaptive immunity, their
uniqueness as nature’s adjuvant has attracted the attention of the scientific
community (Steinman et al. 2000, Steinman et al. 2007, Nagl et al. 1997,
Masten et al. 2006). As such, researchers have begun taking advantage of
their functional roles within the immune system as vaccine targets for
therapeutic antibodies (Chames et al. 2009, Dimitrov et al. 2010). Because of
the roles DCs play and their natural propensity for receptor-mediated
endocytosis, it only seems fitting for therapeutic antibodies to be viewed as a
viable option for therapy against the human immuno-deficiency virus (HIV),
cancer, and other autoimmune diseases; researchers have even considered it
to be a viable delivery vehicle in cases of cancer (Tacken et al. 2007, Dimitrov
et al. 2010, Steinman et al. 2006, Steinman et al. 2000, Kreutz et al. 201).
These therapeutic targeting antibodies have demonstrated moderate success
in past clinical trials (Tacken et al. 2007, Steinman et al. 2006).
A monoclonal antibody (mAb) that has proven to be effective in raising
robust and sustained immune responses is the αDEC-205 antibody (Boscardin
et al. 2006). In past in vitro research, the αDEC-205 antibody has proven a
capable delivery vehicle of tumor antigen that showed to elicit broad range
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antigen specificity (Tsuji et al. 2010). Due to its targeting abilities, the αDEC205 antibody elicits sustained immune responses to co-delivered vaccine
antigens (Bonifaz et al. 2002, Bonifaz et al. 2004, Bozzaco et al. 2007, Tacken
et al. 2007, Jiang et al. 1995, Mahnke et al. 2000, Boscardin et al. 2006).
During immunizations, this antibody, when co-delivered with antigen, targets
the DEC-205 endocytic receptor that internalizes the antibody-antigen
complex (Bonifaz et al. 2002, Bozzaco et al. 2007, Mahnke et al. 2000). DCs
display the processed antibody-antigenic peptides in the Major
Histocompatibility Complex (MHC) molecule’s binding groove on the cell’s
surface for presentation to specific CD4+ T cells (Steinman et al. 2000, Koren
et al. 2007). When CD4+ T cells bind to the peptide-MHC complex, this forms
the immunological synapse, a key interaction between DCs and T cells that
initiate the adaptive immune response (Janeway et al. 2001, Male et al. 2006).
As the adaptive immune response is called into action, two types of immune
responses can be induced: either a tolerogenic or an effector-pro-inflammatory
immune response (Janeway et al. 2001, Male et al. 2006).
In previous BALB/C-C57BL/6 mice immunizations involving αDEC205:OVA antibody absent of co-stimulatory molecules, a tolerogenic immune
response was observed in both in vitro and ex vivo cultures (Bonifaz et al.
2002). Further studies confirmed that the tolerogenic immune response was
not induced due to the attached vaccine antigen, ovalbumin. The results
showed that even when the αDEC-205 antibody was coupled with various
antigens, the tolerogenic immune response remained induced because a co-
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stimulatory molecule was not present during immunizations (Bonifaz et al.
2002, Bonifaz et al. 2004, Tacken et al. 2007, Matos et al. 2013). This
suggested that the antibody itself, rather than the various attached antigens,
induced the tolerogenic immune response. Strong inflammatory T cell
responses were only generated with co-administration of a maturation factor
(αCD40) or adjuvant (Steinman et al. 2000, Bonifaz et al. 2002, Matos et al.
2013)
The tolerogenicity finding is well supported by De Groot et al. (2008)
who demonstrated that the presence of T-regulatory cell epitope sequences
(Tregitopes) within antibody sequences activates regulatory T cells (Tregs)
(modulators of the immune system that prevent it from reacting against selfantigen by readily inducing a tolerogenic immune state) (Josefowicz et al.
2012, Cousens et al. 2013). De Groot and colleagues hypothesized that
various natural T regulatory cell epitopes that are highly conserved amongst
human and mouse Immunoglobulin G (IgG) cause the tolerogenic effect (De
Groot et al. 2008, De Groot et al. 2013). When those particular sequences
were presented, an increase in regulatory T cell expansion
(CD4+CD25+FoxP3+) and activation was detected in studies involving
Tregitope stimulation of peripheral blood mononuclear cells (PBMCs) (De
Groot et al. 2008, De Groot et al. 2013). It is these Tregitopes within α-DEC205’s antibody sequence that are thought to promote tolerance and require
the use of a non-specific immuno-stimulator. If the Tregitopes can be located
and modified, it is then possible that the αDEC-205:OVA antibody may be
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rendered less tolerogenic, thereby improving its capacity to induce a proinflammatory immune response without non-specific activation of the immune
system. This is a novel approach that has not been performed prior.
The purpose of this study is to locate and modify tolerogenic Tregitopes
within the αDEC-205 sequence, to prevent them from being presented on
MHC molecules and subsequently induce a Treg suppressive immune
response. Criteria pre-determined by in silico algorithmic tools identifies MHCII restricted, putative T cell epitope sequences and generates suggested
amino acid modifications to the targeted T cell epitopes in order to reduce
binding potential to the MHC-II molecules. Suggested modifications are then
incorporated into full-length variant αDEC-205:OVA-ORG (original) antibodies.
These variant αDEC-205:OVA antibodies are then tested in an array of
memory response-immunogenicity assays to determine if the variant
antibodies can induce greater levels of pro-inflammatory immune responses,
rendering each antibody less tolerogenic due to the specific modifications
applied to each antibody’s specific Tregitope sequence. These modifications
would lead to an improved DC-targeted vaccine platform system that could
potentially safely and effectively deliver vaccine test antigens to target T cells
by way of the DEC-205 endocytic receptor, found ubiquitously on DCs
(Steinman et al. 2000, Bonifaz et al. 2002, Bonifaz et al. 2004, Tacken et al.
2007).
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CHAPTER 2

REVIEW OF LITERATURE

Dendritic cells and the Host Defense
A functional priority of immature DCs is to capture antigen, found while
patrolling the periphery, and relay acquired processed antigenic peptides to
naïve T cells (Steinman et al. 2000, Lipscomb et al. 2002, Hart, 1997,
Janeway et al. 2001, Tacken et al. 2007, Wilson et al. 2004). Immature DCs
require specialized receptors to recognize and capture antigen (Steinman et
al. 2000, Lipscomb et al. 2002, Hart, 1997, Janeway et al. 2001, Wilson et al.
2004). During an infection, DCs are attracted to sites of inflammation via
environmental stimuli, where the processes of engulfing invading
microorganisms, foreign bodies, or apoptotic self-tissues via phagocytosis and
endocytosis occur (van Vliet et al. 2007, van Vliet et al. 2008, Lipscomb et al.
2002). To defend the host and opsonize pathogens, DCs use pattern
recognition receptors (PRR) that are highly evolutionarily conserved, germlineencoded receptors, expressed on DC cell surfaces (Kerrigan et al. 2011,
Wilson et al. 2004, Pyz et al. 2006). These PRRs recognize characteristics
specific to bacterial or viral components known as pathogen-associated
molecular patterns that include lipopolysaccharides and peptidoglycans
(PAMPs) (van Vliet et al. 2007, Pyz et al. 2006, Kerrigan et al. 2011, Granucci
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et al. 2005). PRRs are present in high quantity on immature DCs and are most
notably represented by Toll-like receptors (TLRs) and C-type lectin receptors
(CLRs) (Pyz et al. 2006, van Vliet et al. 2007 den Dunnen et al. 2012, Wilson
et al. 2004). PRR activation leads to intracellular signaling and triggers innate
immunity, initiating a cascade of events that include secretion of cytokines and
the up-regulation of cell surface receptors, which further define the process of
DC maturation and T cell interaction (Granucci et al. 2005, Kerrigan et al.
2011, Steinman et al. 2001, Tacken et al. 2007, Hart, 1997, van Vliet et al.
2007, Wilson et al. 2004). Ultimately, this process results in a DC-tailored
pathogen-specific adaptive immune response that leads to modulation of
subsequent cellular and humoral immune responses (Ueno et al. 2007, Kreutz
et al. 2012, Granucci et al. 2005, Kerrigan et al. 2011, Tacken et al. 2007,
Geijtenbeek et al. 2009, Steinman et al. 2000, Wilson et al. 2004).
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C-type Lectin Receptors

Figure 1. A dendritic cell and its various C-type lectin receptors
(CLRs). These receptors can be found on various subsets of
DCs. C-type lectin receptors mainly bind to carbohydrate
moieties specific to pathogens, such as peptidoglycan. This
recognition process is mediated by the carbohydrate recognition
domains and is Ca2+ dependent, a hallmark of classical CLRs.
Image provided from Figdor et al. 2002.

Both TLRs and CLRs are crucial for DC recognition of pathogen and
damaged self-tissue, as well as in “self-homeostasis” (Kerrigan et al. 2011,
van Vliet et al. 2007, Steinman et al. 2000, Steinman et al. 2006, Van Kooyk et
al. 2008). CLRs, in particular, represent a large superfamily of membraneassociated DC surface-protein receptors that share primary structural
homology in the carbohydrate-recognition domains (CRD) (Varki et al. 2009,
Kerrigan et al. 2011, van Vliet et al. 2007). Further CLR classification is
decided by the consensus, primary-protein sequence, a 115-130 amino acid
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length sequence, found within the folded lectin domain of the CRD that
primarily determines carbohydrate-binding specificity (van Vliet et al. 2007,
Varki et al. 2009, Hart, 1997, Wilson et al. 2004). Numerous pathogens
express cell-surface carbohydrate structures that function as pathogenspecific “sugar-fingerprints” that the CLRs, mediated by the CRD, recognize in
a calcium dependent manner, a hallmark of classical CLRs (den Dunnen et al.
2012, Pyz et al. 2006, Hart, 1997, Varki et al. 2009).
Immature DCs express a variety of CLRs; classic examples are the
Mannose receptors (MR) (CD206), DEC-205 receptors (CD205), Dectin-1 and
Dectin-2 receptors, DC-SIGN, Mincle, and asialoglycoprotein receptors (Figure
1) (Tacken et al. 2007, Tel et al. 2011, van Vliet et al. 2007, den Dunnen et al.
2012, Mahnke 2000, Idoyaga et al. 2008). All of these receptors have the
capacity to capture glycosylated antigen and mediate interactions between
specific pathogens and tailor immune responses (Van Kooyk et al. 2008,
Tacken et al. 2007, Steinman et al. 2000, Tel et al. 2011, Wilson et al. 2004).

The Multi-lectin DEC-205 Receptor
Several CLRs have demonstrated the proclivity to not only capture
specific antigen, triggering an innate immune response, but also facilitate
efficient loading of antigen onto MHC Class I and Class II molecules (Rutella
et al. 2006, Lipscomb et al. 2002, Hart, 1997, Tacken et al. 2007, van Vliet et
al. 2007, den Dunnen et al. 2001, Idoyaga et al. 2008). Thus, CLRs have been
explored as target receptors for targeted antigen delivery via antibodies
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(Kreutz et al. 2012). One receptor in particular that shows such functional
tendencies is the DEC-205 receptor (Tacken et al. 2007, van Vliet et al. 2007,
Lahoud et al. 2012, Kreutz et al. 2012).
The DEC-205 receptor is a C type-1 multi-lectin endocytic receptor that
is found ubiquitously on DC surfaces; however, they are also found on various
immune cells such as macrophages, B cells, and T cells at varying levels of
expression dependent on cell-state maturation (Shrimpton et al. 2009,
Steinman et al. 2006, Bonifaz et al. 2004, Mahnke et al. 2000, Tacken et al.
2007, Lahoud et al. 2012, Caminischi et al. 2012, Kato, 2006). DEC-205 is a
205 kD integral membrane protein receptor, homologous to the macrophage
mannose receptor, that has a cysteine-rich domain, a fibronectin type II
domain, and 10 extracellular, contiguous, C-type lectin-like domains (Lahoud
et al. 2012, Mahnke, 2000). The DEC-205 receptor binds to specificpathogenic carbohydrate moieties in a calcium dependent manner, and takes
part in the receptor-mediated endocytic process (Tel et al. 2011, van Vliet et
al. 2007, Steinman et al 2006, Geijtenbeek et al. 2009). Within the DEC-205
receptor’s distinct distal region of the cytosolic tail is an internalization
sequence (requisite coated pit localization sequence) consisting of an acidic
EDE triad, which facilitate receptor-mediated endocytosis and efficient
recycling through late endosomal/lysosomal compartments (Lahoud et al.
2012 Jiang et al. 1995, Varki et al. 2009, Geijtenbeek et al. 2009, Steinman et
al. 2000, Mahnke et al. 2000).
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Immunotherapy - Targeted antibodies
There have been a number of treatment options such as surgery,
chemotherapy, or pharmaceutical drugs over the years to try and treat most
forms of autoimmune diseases, tumors, and cancers (Tacken et al. 2007,
Steinman et al. 2000). However, within the past decade, immunotherapy has
started to increase in popularity and become a viable option for disease
treatment. In immunotherapy, a body’s own immune system is used to help
fight off infection and disease (Lipscomb et al. 2002, Tabrizi et al. 2006). For
example, either immune system’s cells are used to elicit a general immune
response or mAbs are used to induce an antigen-specific immune response
(Lipscomb et al. 2002, Tacken et al. 2007, Steinman et al. 2000, Tabrizi et al.
2006). Cellular-based immunotherapy clinical studies, for example, utilize
autologous DCs, ex vivo cultured, which are stimulated and loaded with tumorlysate antigen (Tacken et al. 2007). These DCs are then re-introduced to
patients as a form of cellular vaccination against tumors (Tacken et al. 2007,
Steinman et al. 2000).
A benefit to this type of vaccination is that cells are stimulated outside
of the body, preventing non-specific systemic activation often associated with
most vaccines and attributed to the harmful side effects of vaccines, ranging
from soreness at the injection site to systemic distress (Stills et al. 2007,
Tacken et al. 2007). However, there are limitations associated with cellularbased immunotherapy: availability of readily isolated DC subsets or
precursors, isolation of a sufficient number of DCs, in vitro culture capacity of
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isolated subsets, and DC distribution once administered to the patient (Tacken
et al. 2007).
Those limitations and the need for an improved approach lead to the
development of antibody targeted immunotherapy against autoimmune
diseases, the human immunodeficiency virus (HIV), and cancers (Steinman et
al. 2000, Tacken et al. 2007, Lahoud et al. 2012, Lipscomb et al. 2002, Rutella
et al. 2006, Pyz et al. 2006, Bonifaz et al. 2004). Given the unique roles DCs
play in innate and adaptive immunity and the various cell surface receptors
found on DCs capable of endocytotic processes, strident efforts were made to
harness and utilize DCs to develop a novel immuno-therapeutic vaccine
strategy involving targeted delivery of antigens to resident DCs (Steinman et
al. 2000, Tacken et al. 2007, Rutella et al. 2006, Tel et al. 2007, Boscardin et
al. 2006). This approach became a viable option in patient care because
mAbs’ provide beneficial vaccine specificity, which directly target the choicereceptor, requiring less dosage of antigen, and as a result lessens the harmful
impact of non-specific activation (Tacken, Steinman, Chan, 2010, Rutella et al.
2006, Pyz et al. 2006, Torchillin et al. 2003, Tabrizi et al. 2006).
Proof of principle-clinical trials reported that initial targeting of DCs by
mAbs in vivo lead to favorable ex vivo immune responses once autologous
DCs were re-stimulated with antigen (Tacken et al. 2007). Further studies
reported the same results, that mAbs are capable of effectively targeting
specific receptors for uptake of antigen and immunize against a specific
pathogen, though in some cases immune responses were reported to be
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limited in regards to various forms of cancer and tumors (Tacken et al. 2007,
Lipscomb et al. 2002, Bonifaz et al. 2004, Steinman et al. 2000, Singh et al.
2012). Reports also indicated that targeting antigen to DCs in vivo not only
showed cellular immune responses, but also a boost in humoral immune
responses (Caminschi et al. 2012).

αDEC-205 Antibody
Past studies showed that the DEC-205 receptor is an effective
endocytic receptor capable of internalizing targeted antigen with subsequent
presentation of antigen on MHC molecules, on the DC surface, to CD4+ and
CD8+ T cells (Bonifaz et al. 2002, Steinman et al. 2006, Tacken et al. 2007,
Caminschi et al. 2012, Corbett et al. 2012, Boscardin et al. 2006, Kato, 2006).
Previous studies have shown that antigen targeted to the DEC-205 receptor is
two orders of magnitude more effective at inducing T cell proliferation and IFNγ secretion rather than non-targeted antigens (Boscardin et al. 2006). Thus, a
therapeutic antibody capable of targeting the DEC-205 receptor was selected
to move forward with. αDEC-205:OVA (original) (ORG) is a chimeric mAb that
has a rat variable region and a mouse constant region. It is a recombinant
fusion protein with full-length ovalbumin whole protein attached to both ends of
the αDEC-205 antibody’s heavy chains. Ovalbumin is a known mouse
immunogen that readily induces antigen-specific cellular and humoral
mediated immune responses (Sun et al. 2010). Nevertheless, the αDEC-205
antibody is like any other IgG molecule containing both a F’ab (antigen binding
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fragment) and Fc region (fragment crystallizable region) that consists of four
polypeptide chains: two light chains and two heavy chains, each with their own
constant and variable regions and connected by disulfide bonds (Janeway et
al. 2001, Kumagai et al. 2001).

MHC Class II Processing Pathway

Figure 2. The Class I and Class II antigen-presentation pathways
found in all dendritic cells. The MHC I molecule presents
peptides that are derived from endogenous proteins that are
degraded generally in the cytosol. The MHC II molecule presents
peptides that are derived from exogenous protein and degraded
by proteolytic enzymes within endosomal compartments.
Image provided by Villadangos et al. 2007.

Previous research has shown the αDEC-205:OVA antibody to directly
target the DEC-205 endocytic receptor, found ubiquitously on dendritic cells,
where after receptor-mediated endocytosis occurs (Mahnke et al. 2000,
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Steinman et al. 2006, Tacken et al. 2007, Nagl et al. 2002, Bonifaz et al.
2002). Following the receptor-ligand internalization, the antibody-antigen
complex is loaded into a late endosome, which initiates the Major
Histocompatibility Complex Class II (MHC II) processing pathway (Steinman et
al. 2000, Bonifaz et al. 2004, Tacken et al. 2007, Holling et al. 2004, Mahnke
et al. 2000). The DEC-205 receptor facilitates the targeting of late endosomes
to load the receptor-ligand complex, due to the coated pit localization
sequence in the cytosolic tail (Lahoud et a. 2012, Jiang et al. 1995). The late
endosomes are specific to the MHC II pathway and eventually fuse with
lysosomes containing internal proteases (Janeway et al. 2001, Male et al.
2006, Lahoud et al. 2012, Bonifaz et al. 2002, Steinman et al. 2007). The low
pH of the vesicle enables the antibody-antigen complex to dissociate from the
DEC-205 receptor and proteolytic processing begins, generating antibody and
antigenic peptide fragments (Janeway et al. 2001, Mahnke et al. 2000, Tacken
et al. 2007, Lahoud et al. 2012, Bonifaz et al. 2002, Steinman et al. 2006,
Varki et al. 2009). Concurrently, MHC II formation initiates in the Endoplasmic
Reticulum (ER) (Male et al. 2006, Janeway et al. 2001).
There are two types of MHC molecules, Class I (MHC I) and Class II
(MHC II) (Janeway et al. 2001). Both are uniquely inherited proteins and are
the ultimate molecules presenting the peptide fragments generated through
the MHC processing pathway (Janeway et al. 2001). The type of antigen
engulfed (viral, bacterial) and its location to the cell (extracellular, intracellular)
determines which of the two MHC molecules is used and which pathway
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(Class I or Class II) to initiate (Janeway et al. 2001, Male et al. 2006). The
MHC I molecule generally deals with intracellular antigens such as virus
infected cells, while MHC II molecules generally present peptides from
extracellular proteins, such as from bacteria (Janeway et al. 2001, Steinman et
al. 2000, Mahnke et al. 2000). Since an extracellular antibody-antigen protein
is targeting the DC, an MHC II molecule will present the peptide fragments
(Figure 2) (Janeway et al. 2001).
An MHC II molecule is a cell surface protein heterodimer with 2
homogenous polypeptide chains (α, β) consisting of 2 intracellular, transmembrane, and extracellular domains (Mangalam et al. 2013). The 2
extracellular polymorphic domains (α1, β1) result in the formation of the openended antigenic peptide-binding groove (Mangalam et al. 2013, Janeway et al.
2001). For the MHC II molecule, there are 3 pairs of α- and β-chain genes,
called HLA-DR, -DP, and –DQ (Janeway et al. 2001, Male et al. 2006). With
several possibilities of different genes for each MHC II molecule, an individual
is capable of recognizing and presenting a broader range of antigenic peptides
(Janeway et al. 2001). The MHC II in humans is referred to as Human
Leukocyte Antigen (HLA) complex and H-2 in mice (Janeway et al. 2001).
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Figure 3. Peptide bound to an MHC II molecule. This is a top view of
a MHC II molecule with a specific peptide antigen (Influenza HA
peptide 3006-318) bound in the MHC II molecule’s binding groove.
Key peptides can be seen anchoring the peptide into the binding
groove. This peptide-MHC complex is displayed on the dendritic cell
surface for presentation to naïve T cells in the lymph nodes. Image
from Neefjes and Ovaa, 2013.

During this MHC II processing pathway, while the MHC II forms in the
ER, an invariant (li) chain also forms (Janeway et al. 2001, Male et al. 2006).
The li is ultimately situated in the MHC II peptide-binding groove, and acts as a
chaperone-peptide throughout the MHC II molecule’s travel to the Golgi
apparatus (Janeway et al. 2001). The li chain forms a core trimer that
associates with the 3 MHC II αβ subunit-dimers and results in a nonameric
complex incapable of binding antigenic peptides, which is important since
endogenous peptide fragments are present in the ER during the MHC II
formation (Yan et al. 2003).
The li chain secures the MHC II’s peptide binding groove and the MHC
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II-li complex undergoes extensive glycosylation to reach the late
endosomal/lysosomal’s vesicle antigen processing compartments after leaving
the Golgi apparatus (Yan et al. 2003, Janeway et al. 2001). A series of highly
regulated proteolytic cleavages along with a HLA-DM accessory protein
catalyzes the final release of the last li chain fragment, altogether known as
the Class II associated invariant peptide (CLIP), and facilitates the binding of
antigen to the binding groove (Yan et al. 2003). With the li chain removed, the
MHC II peptide-binding groove presents specific antigenic peptide fragments
(Yan et al. 2003, Mahnke et al. 2000).
The crystal structure of an MHC II shows that the antigenic peptidebinding groove can accommodate peptide fragments between 12-25 amino
acids in length (De Groot et al. 2008, Mangalam et al. 2013). The core 9mer
peptide binds non-covalently, but is held in place at key anchor sites within the
binding groove (positions 1, 4, 6, and 9) (De Groot et al. 2008, Mangalam et
al. 2013, Male et al. 2006). Peptides are chosen based on stability, charge,
and binding affinity to the MHC II molecule (De Groot et al. 2008, Mangalam et
al. 2013, Parker et al. 2010, De Groot et al. 2009). The peptide-MHC II
formation results in a stable complex that travels to the DC surface for
presentation to its target cell population, CD4+ T cells (Holling et al. 2004,
Steinamn et al. 2000, Yan et al. 2003, Mahnke et al. 2000).

DC Migration
Now DCs undergo a maturing differentiation process, which is
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facilitated by the uptake of antigen and subsequent generation of peptides
(Steinman et al. 2000, Steinman et al. 2007, Tacken et al. 2007, Lahoud et al.
2012, Wilson et al. 2003). Antigen processing primes the immature DCs to
initiate intracellular signaling, secrete cytokines, modulate cell surface receptor
expression, and further signals the DCs to migrate from the tissue periphery
via the lymphatic system to the draining lymph node, the site of antigen
localization and naïve T cell priming (Steinman et al. 2007, Janeway et al.
2001, Lahoud et al. 2012, Lipscomb et al. 2002, Mahnke et al. 2003). During
this process, immature DCs outwardly change their appearance to possess
more finger-like structures that protrude from the main body to increase
surface area multifold; this morphological change better represents their new
primary role of antigen presentation via MHC molecules (Lipscomb et al. 2002,
Bonifaz et al. 2002, Steinman et al. 2006, Tacken et al. 2007, Wilson et al.
2003).
Immunological Synapse (IS)
Once DCs mature, up-regulation of various “signaling” molecules,
representative of the current cell state appear, such as increased expression
of MHC molecules, cell surface receptors (CD80, CD86, CD40), secretion of
chemokines and cytokines, and adhesion molecules (Steinman et al. 2000,
Lahoud et al. 2012, Lipscomb et al. 2002, Tacken et al. 2007). The current
state of cellular and environmental affairs is represented by the critical
expression of these molecules and is meant to inform other immune cells,
especially T cells whilst the DC is in the lymph node (Steinman et al. 2000,

20

Janeway et al. 2001). The naïve T cells present in the lymph node are
continuously circulating around the DCs, searching for antigenic peptides that
are displayed on MHC II molecules (Steinman et al. 2000).
T cells contain on their surface T cell receptors (TCRs), which are cell
surface disulfide-linked heterodimer receptors similar to the antibody’s F’ab
region (Broere et al. 2011, Janeway et al. 2001, Rudolph et al. 2006). At any
one time, approximately 30,000 TCRs are present on the T cell’s surface with
the majority of TCRs containing a α and β chain (Janeway et al. 2001).
Antigen specificity is determined by TCRs, which recognize and bind to
specific peptides presented by the MHC II molecules, on DC surfaces (Broere
et al. 2011). However, T cells are only capable of recognizing peptides if they
are apart of the peptide-MHC complex (Figure 5) (Broere et al. 2011,
Josefowicz et al. 2012, Janeway et al. 2001). T cell lineage-specific accessory
molecules and adhesion molecules bind to DCs (CD4 or CD8) and facilitate
the process by providing stability to the DC-T cell interaction (Janeway et al.
2001, Broere et al. 2011). Nonetheless, immediately after binding, the naïve T
cell initiates a cascade of events, such as intracellular signaling with -functionassociated protein 1 (LFA-1) and the intracellular adhesion molecule 1 (ICAM1), up-regulates and modulates cell surface receptors (CD28) (CTLA-4), and
secretes cytokines and chemokines (Rudolph et al. 2006, Janeway et al. 2001,
Broere et al. 2011).
This activation process of the T cell informs the DC whether to assume
an inflammatory or regulatory phenotype hereafter, alerts other immune cells
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to the antigens presence, and polarizes T cells, which can result in activation
and expansion of T effector cells and B cells or T regulatory cells (Tregs)
(Broere et al. 2011, Janeway et al, 2001, Mennechet et al. 2006). Overall, this
DC-T cell interaction creates positive and negative feedback loops filled with
information on how to proceed with the antigen-specific immune response
(Broere et al. 2011, Janeway et al. 2001, Steinman et al. 2007).

Figure 4. A mature Immunological Synapse (IS). The IS
represents the events leading up to and the formation of the
nanometer scale gap interaction between APCs and T cells, as
well as the subsequent T cell polarity and signaling pathways
activated by this synapse formation.
Image from Huppa et al. 2003.
This fluid and dynamic interaction between the DC’s MHC II-peptide
complex and the T cell’s TCR is the basis for the immunological synapse (IS)
(Figure 4) (Griffiths et al. 2010, Bromley et al. 2001, Viola et al. 2010,
Steinman et al. 2007, Huppa et al. 2003). The IS encompasses the
environment generated by the coupling of DCs and T cells, such as it relates
to the membrane structure, T cell polarity, signaling compartmentalization, the
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antigen-presenting cell, and quality of antigen presented (Bromley et al. 2001,
Viola et al. 2010, Huppa et al. 2003, Grakoui et al.1999). This interaction
results in T cell activation and the initiation of an antigen-specific T cell
mediated adaptive immune response (Janeway et.al 2001, Male et al. 2006,
Broere et al. 2011, Bromley et al. 2001, Huppa et al. 2003). Thus, antigen
trafficked to the DEC-205 receptor can lead to the generation of either a T cell
effector or regulatory antigen-specific immune response (Steinman et al. 2007,
Tacken et al. 2007, Bonifaz et al. 2002).

Adaptive Immunity

Figure 5. Naïve T cell differentiation. After a naïve T cell recognizes
and binds to a peptide-MHC complex, a cascade of events occurs
intracellularly and extracellularly that allows the naïve T cell to
undergo differentiation. Image from O’Shea and Paul, 2010.
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Adaptive immunity refers to the immune responses generated to a
specific peptide-MHC complex that are then recognized by antigen-specific T
cells (Steinman et al. 2006, Janeway et al. 2001). Adaptive immunity is slow
acting, but it is more specific and targeted against a particular pathogen
(Janeway et al. 2001, Steinman et al. 2007). From adaptive immunity, two
types of IS induced immune responses are possible: A tolerogenic immune
response or an effector immune response (Janeway et al. 2001, Steinman et
al. 2007).
Generally, an effector immune response is generated after T cell
recognition and activation to peptides presented in context of MHC molecules
and co-stimulatory signals provided by APCs (Figure 5) (Steinman et al. 2007,
Janeway et al. 2001). Signal 1 consists on the foreign peptide presented by
the MHC II molecule and signal 2 is provided by the co-stimulatory proteins
produced, up-regulated, or secreted during the IS interaction, such as CD28,
CD80, and CD86 (Janeway et al. 2001, Rudolph et al. 2006, Bromley et al.
2001, Viola et al. 2011). An effector immune response would result in a robust
pro-inflammatory immune response characteristic of pro-inflammatory
cytokines, such as IL-1, TNFα, IFN-y, IL-2, IL-4, or IL-12 (Hart, 1997, Dinarello
et al. 201, Lipscomb et al. 2002, Wilson et al. 2003, Desombere et al. 2004).
A tolerogenic immune response is very similar in process to the effector
immune response as it too is controlled directly or indirectly by the upregulated and secreted proteins resulting from a chain of cellular interactions
initiated by the presentation of bound peptide (Barbosa et al. 2007). However,
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there are a few key differences: The bound peptide is from “self-protein” and
there are limited numbers of cytokines and cell surface receptors present
(Janeway et al. 2001). Those key differences, overall, result in a regulatory
immune response with either the interacting T cell or DC secreting regulatory
cytokines such as TGF-β or IL-10 (Josefowicz et al. 2012). T helper cells will
become activated via the cytokine signaling of TGF-β or IL-10 and differentiate
into Tregs (Male et al. 2006, Josefowicz et al. 2012).

Regulatory T cells
Regulatory T cells (Tregs) are the mediators of the immune system.
Tregs, after activation, secrete regulatory cytokines that inhibit effector T cell
responses. They are featured prominently in autoimmune diseases,
inflammatory disorders, peripheral tolerance, and immune homeostasis
(Josefowicz et al. 2012, Lio et al. 2010, Lee et al. 2014, Burchill et al. 2008).
Tregs are one way for the immune system to protect itself against reacting to
“self-protein”, as well as have the capacity to minimize the effects of
inflammation and damage induced by pathogens (Josefowicz et al. 2012, Male
et al. 2006, Janeway et al. 2001, Lio et al. 2008, Burchill et al. 2008). Tregs
are characterized as suppressive immune cells whose phenotypes are
CD4+CD25+FoxP3+. They require the presence of CD28, IL-2, and to a lesser
extent IL-7 and IL-15, in order to become activated and fully differentiated
(Josefowicz et al. 2012, De Groot et al. 2008, Lio et al. 2008, Burchill et al.
2008). FoxP3 is a forkhead family transcription factor that has come to be
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associated with Tregs, and, though not a definitive marker, its presence still
supports a dedicated function in Treg cell differentiation, as was reported in
FoxP3 reporter mice cells CD4+CD25-FoxP3+ (Josefowicz et al. 2012, Ohkura
et al. 2012).

Induction of a Tolerogenic Immune Response
As reported in past studies, OVA antigen delivered by the
αDEC205:OVA antibody to the DEC-205 receptor is internalized and
processed by DCs (Bonifaz et al. 2002). Processing of the protein complex
generates peptide fragments that are then loaded, if possible, onto the MHC II
molecule for presentation to T cells (Bonifaz et al. 2002, Tacken et al. 2007,
Steinman et al. 2006). Normally, delivery of antigen with this targeted vehicle
induces a tolerogenic immune response when no maturation factor is used
(Bonifaz et al. 2002, Steinman et al. 2006, Tacken et al. 2007, Uto et al. 2013).

Figure 6. The Tregitope-effect concept. This figure depicts the concept
behind the induction of a tolerogenic immune response that is observed
after the αDEC-205:OVA antibody, without a maturation factor, is used
during immunizations. Provided by Weber et al., 2008.
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Presentation of tolerogenic signals or natural T regulatory cell epitopes
(Tregitopes) is hypothesized to induce the tolerogenic immune response when
the αDEC205:OVA antibody is used in immunizations (De Groot et al. 2008,
De Groot et al. 2013). Derived from IgG molecules, Tregitopes are potentially
found in both the F’ab (framework) and Fc regions of an antibody (De Groot et
al. 2008, Cousens et al. 2013). Tregitopes are highly conserved in IgG
molecules and considered highly promiscuous due to binding to various HLA
alleles (De Groot et al. 2008, Cousens et al. 2013). Due to the “foreign” (not
seen in thymic development) somatic hypermutations at the variable region’s
antigen-binding site in IgG molecules, it is hypothesized that highly conserved
sequences (Tregitopes) were retained throughout evolution for self-protein
(IgG molecules) to escape immune system recognition (De Groot et al. 2013,
Janeway et al. 2001, Livesay et al. 2004).
Published findings show an induction of tolerance owing to Treg
expansion (CD4+CD25+FOXP3+) when Tregitope sequences are co-cultured
with peripheral blood mononuclear cells (PBMCs) (De Groot et al. 2013).
These studies were eventually replicated by Zambidis and Scott (1996) and
found that an IgG’s heavy chain fused to antigen induced tolerance as well,
where current human Tregitopes (167 and 289) are found in the constant
heavy chain FC region (De Groot et al. 2008). Thus, Tregitopes, found within
the αDEC-205 antibody’s sequence, are thought, once presented by MHC II
molecules, to activate Tregs, upregulate Treg associated cytokines and
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chemokines, and subsequently induce an antigen-specific regulatory immune
response (De Groot et al. 2008, Singh et al. 2012, Cousens et al. 2013).

Proposed Objective

Figure 7. A 3-D model of the αDEC-205 antibody with the targeted
Tregitopes highlighted in blue and red. Tregitopes or natural T
regulatory cell epitopes are potentially highly conserved sequences
found in all IgG molecules. When Tregitopes are presented they are
believed to induce CD4+CD25+FoxP3+ regulatory T cells. Two
Tregitope sequences, HC54 and VH77, are highlighted in red and
blue, respectively. HC54 sequence (red) is found in the constant
heavy chain region and the VH77 sequence (blue) is located in the
variable heavy chain region. Model provided by Dr. Yoonjoo Choi
and Dr. Chris Bailey-Kellogg (Dartmouth).
Adjuvants are believed to be required for the αDEC205:OVA antibody’s
targeted antigen delivery due to Tregitope presence in the IgG delivery vehicle
(De Groot et al. 2008). Adjuvants are used to induce a robust and sustained,
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strong T cell mediated immune response to the specific antigen fused to the
antibody (Steinman et al. 2000, Hill et al. 2007). Therefore, selected Tregitope
sequences within the αDEC-205:OVA antibody are modified to diminish
tolerogenicity, which will inhibit Treg activation, and promote immunogenicity
to less immunogenic peptides, such as the vaccine test antigen, ovalbumin.
This approach removes the need for non-specific activation of the immune
system (De Groot et al. 2008, Moise et al. 2012).
The proposed objective is to compare the variant αDEC-205:OVA
immunization conditions’ immunized splenocytes’ responses to the nonmodified αDEC-205:OVA-ORG immunization condition’s immunized
splenocytes’ responses. Splenocyte responses are observed in two
immunogenicity assays to determine if a greater pro-inflammatory immune
response, characteristic of T cell proliferation and pro-inflammatory cytokine
signaling, is observed when immunizing mice with the Tregitope modified
antibody sequences. This will help to uncover whether Tregitopes are the
cause for tolerogenic effects when antigen is administered in the absence of
an adjuvant.
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CHAPTER 3

MATERIALS AND METHODS
Mice
HLA-DRB1*0401 (DR4) mice are a transgenic humanized HLA mouse
model derived from a C57BL/6 background that are used to test vaccine
efficacy and T cell responses specific to the DR4 allele (Ito et al.1996). The
DR4 mice are brought in from Taconic and cared for in-house in the bio-safety
level 2 (BSL-2) trailer located at Peckham Farm on the University of Rhode
Island’s Kingston campus (Ito et al.1996, Grusby et al.1991). The mice
founders of this transgenic line were initially crossed with MHC II deficient
mice (Genpharm C2d line), which has the I-A beta gene inactivated and the
unexpressed I-E alpha allele found in the C57BL/6 haplotype (Ito et al. 1996,
Grusby et al. 1991). Mice contain hybrid MHC II molecules that contain the
peptide binding domain specific to the HLA-DRA and HLA-DRB1*0401 allele
(Ito et al. 1996, Grusby et al.1991).

Antibodies
The αDEC-205 antibody recombinant expression constructs were
obtained from Dr. Ralph Steinman (The Rockerfeller University). Aldevron
produced the high titers (1 mg/mL) of the original wild type αDEC-205 antibody
(ORG) and modified antibodies αDEC-205:OVA-CH54-MOD1, αDEC-
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205:OVA-VH77-MOD1, αDEC-205:OVA-VH77-MOD2 (MODs). αDEC-205 is a
chimeric, monoclonal, rat-α-mouse antibody that is transfected and expressed
in the Chinese Hamster Ovary (CHO-S) cells mammalian expression system
(Invitrogen-Life Technologies R800-07). The ovalbumin whole protein (45 kD),
a major component of chicken egg white, was recombinantly fused via linker
protein sequence to the C-terminus of the αDEC-205 heavy chain (Yasushi).
The staining antibodies used in the imunogenicity assays are
purchased from eBioscience, BDBiosciences, or Life Technologies
(Affymatrix) and can be viewed in the table below (Table 1-2). The fluorescent
cell-staining dye, CFSE (Carboxyfluorescein succinymidal ester) was
purchased from Life Technologies.

Table 1. The JAWS II DC binding assay antibody staining
panel.
Antibody/Stain

Manufacturer

Clone

αms-IgG-FitC

eBiosciences

GK5.1

αCD11c-PE-Cy7

eBiosciences

145-2C11

Table 2. The T cell proliferation assay antibody staining
panel.
Antibody/Stain

Manufacturer

Clone

αCD4-BV 421

BD Biosciences

GK5.1

αCD8a-APC

BD Biosciences

53-6.7

αCD3e-PE

BD Biosciences

145-2C11

CFSE

Life Technologies
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n/a

JAWS II Dendritic Cells
A bone marrow derived-C57BL/6 background dendritic cell line, JAWS
II DCs (ATCC-CRL-11904), are passaged once weekly at a 2:1 (cells: culture
media) ratio utilizing αMEM culture media supplemented with deoxy and ribonucleosides, 5% L-glutamine 100x (Invitrogen 25030-156), 5% Sodiumpyruvate (Hyclone-SH3023901), 10% Fetal Bovine Serum (Invitrogen 10100147), 5% Penicillin/Streptomycin (Invitrogen 15140-122), and Granulocyte
Macrophage-Colony Stimulating Factor-Recombinant Mouse (R&D systems:
415ML010) in T-75 flasks, as per manufacturer’s (ATCC) instructions (ATCCCRL-11904).
Immunoinformatics Analyses: The EpiMatrix System
EpiMatrix
The αDEC-205 sequence was computationally screened for putative
HLA-Class II restricted conserved T cell epitopes with the use of an in silico
tool, EpiMatrix (Table 1). EpiMatrix identifies which 9 amino acid frames are
predicted to bind to specific HLA alleles and are highly conserved in existing
databases of IgG sequences (De Groot et al. 2013, De Groot et al. 2014).
Protein antigens are parsed into overlapping 9-mer frames. Each 9-mer frame
overlaps the last frame by eight amino acids. 9-mer frames are scored against
a panel of 8 class II “supertype” alleles that comprise at least 90% of the
world’s human HLA genetic makeup to determine the epitope’s binding
potential to each of the 8 common class II alleles: DRB1*0101, *0301, *0401,
*0701, *0801, *1101, *1301, and *1501 (De Groot et al. 2008, Cousens et al.
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2013, Singh et al. 2012). The EpiMatrix algorithm compares the amino acid
sequence of each 9-mer frame to the coefficients contained in the matrix,
which produces a raw score for each frame. The raw score is then converted
to a normalized z-scale. The EpiMatrix z-scale provides z-scores, allowing for
comparison of potential epitopes to multiple class II HLA alleles (De Groot et
al. 2008, Singh et al. 2012). Peptides scoring ≥ 1.64 (top 5th percentile) on the
EpiMatrix “Z”-scale are predicted MHC II ligands. The higher the EpiMatrix “Z”
score, the more likely the peptide sequence is an MHC ligand and a T cell
epitope (De Groot et al. 2008). The EpiMatrix Cluster analyses reported
predictions for each 9mer frame sequence with top 10% z-scores (hits) or
greater. The relevant z-scores can be read as follows, top 10% hits are
highlighted in the lightest blue, the top 5% hits in a bluish-grey, and the top 1%
hits are highlighted in dark blue (Table 5). The top 1% and 5% hits reported in
all the EpiMatrix Reports have z-scores ≥ 2.30 and scores between 1.64-2.29,
respectively (Table 5).
ClustiMer
ClustiMer is a ancillary algorithm used with EpiMatrix analyses and
identifies areas densely laden with putative T cell epitope clusters with highscoring EpiMatrix z-scores throughout the entire antibody sequence
(Sintechenko et al. 2010). More specifically, ClustiMer maps the EpiMatrix
motif matches along the length of a protein and calculates the density of motifs
against the panel of eight HLA alleles (De Groot et al. 2008, Sintechenko et al.
2010). T cell epitope clusters with ClustiMer scores ≥ 10 indicate a significant
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potential for immunogenicity for a given epitope sequence. Clusters usually
range between 9-25 amino acids in length and can have 4-40 binding motifs
(De Groot et al. 2008). All high scoring putative T-cell epitope clusters
ultimately are compared to human IgG sequences and only cluster sequences
showing homology to human IgG, potentially regulatory sequences, were
selected for targeted modification, to reduce binding potential to the HLADRB1*0401 allele (De Groot et al. 2008, Caspi, 2008, Parker et al. 2010).
OptiMatrix
OptiMatrix, the final algorithm, identifies amino acids contributing the
most to the T cell epitope’s HLA binding affinity to a specific allele and targets
the amino acids for select modifications, to reduce binding potential (De Groot
et al. 2008). Each epitope sequence modification is dependent on the
individual amino acid’s binding affinity to the MHC II molecule and the
predicted effect it will have on the HLA binding affinity (De Groot et al. 2008).
Only amino acid substitutions that resulted in the reduction of the epitope
sequence’s EpiMatrix z-score were chosen for potential incorporation into the
full-length αDEC-205:OVA-ORG antibody. A reduction in the predicted
EpiMatrix z-score correlated to that particular epitope sequence’s decrease in
predicted binding affinity for a given HLA-allele (Moise et al. 2012, De Groot et
al. 2008). Generally, amino acids located within the MHC II anchoring peptide
positions are modified first, since those amino acids are key to that peptide’s
affinity to the MHC molecule (De Groot et al. 2008). Normally, both alanine or
glycine are chosen as amino acid replacements because they are least likely
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to interact with the surrounding peptides within the MHC II molecule’s binding
groove and provide less steric hindrance (De Groot et al. 2008). Alanine
substitutions have shown in previous work by Warmerdam et al. to result in
de-immunization of the epitope and reduce or eliminate a subsequent T cell
response (Schönbach et al. 2008).
Site Directed Mutagenesis
The suggested modifications were incorporated into the full-length
αDEC-205:OVA sequence by Site Directed Mutagenesis to produce an array
of αDEC-205 antibody variants via Stratagene’sQuikChange® XL II SiteDirected Mutagenesis Kit, per manufacturer’s instructions. The procedure
enables site-specific mutations within double-stranded plasmids and
eliminates the need for specialized vectors and unique restriction sites. Normal
thermo-cycling procedures involving denaturation of plasmid at 95°C for 1
cycle, annealing of the mutagenic primers complementary to opposite strands
of the plasmid, and subsequent elongation of the mutagenic primers for 18
cycles, resulting in the synthesis of mutant strands (Quik Change XL II200522). Left over hemi-methylated and methylated parental DNA strands
were removed by Dpn I endonuclease digest. Resulting nicked-mutant strands
were then transformed into XL10 gold bacterial cells where ligation and
subsequent transformation into bacterial cells occur (Quik Change XL II200522). Newly transformed XL 10 gold bacterial cells containing the mutant
strands were streaked on Agarose gel plates containing ampicillin.
Immediately following, streaked plates were placed in a 37ºC incubator for
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overnight cell growth. Only bacterial cell colonies that had properly taken in the
plasmid and potentially the mutagenic strands would have been able to grow
due to antibiotic resistant genes present within the plasmid. Thus, colonies
were chosen the following morning for plasmid purification purposes. The very
same day, plasmid DNA was isolated from the top 10 cells via lysing
techniques and purified using Qiagen-mini prep techniques (QIAGEN-Kit Cat.
No. 27104). The purified plasmids containing the select amino acid
modifications to targeted potential Tregitope sequences were sent for
confirmatory sequencing and high production yields (1 mg/mL) of low
endotoxin plasmid to Aldevron.

Transfection of CHO-S cells
Chinese Hamster Ovary-S cells (CHO-S) (R800-07) were passaged
day prior to transfection, at 5 x106 cell/mL in FreestyleTM CHO Expression
Media (12651-014) as per manufacturer’s instructions (Invitrogen-Life
Technologies-K9000-20). Flasks were placed in an orbital shaker platform
(120-135 rpm) at 37ºC, 8% CO2. On the day of transfection the CHO-S cell
density must range between 1.2-1.5 x106 cell/mL. Cells were counted via
Cellometer and the live cell viability is recorded. A 95% cell viability or greater
is also required to ensure high transfection results. 30 million cells were taken
from the repository culture flask and were loaded into a new 125 mL culture
flask that is placed into a 37ºC incubator for acclimation purposes.
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Immediately following, 37.5 ug of each respective plasmid DNA is
aliquoted into FACS test tubes and mixed with 0.6mL/test tube of OptiProTM
SFM (123-9-050). Concurrently, in separate tubes, the FreestyleTM MAX
Transfection Reagent (16447-100) is diluted with up to 0.6mL/test tube of
OptiProTM SFM. Plasmid DNA preparations were mixed with their respective
transfection reagent-OptiPro solutions, yielding mixed transfection reagentDNA solutions. Mixed DNA-transfection solutions incubated for 10 minutes
(min.) at room temperature, enabling formation of plasmid DNA-reagent
complexes. The DNA-reagent complex solutions were added to the respective
previously acclimated 125 mL culture flasks. Culture flasks were then loaded
into the orbital shaker platform within the 37ºC, 8% CO2 incubator for a
maximum of 7 days (Invitrogen). During the 7-day time frame, cell viability is
checked everyday to determine the optimal “harvest” day. Generally, cells are
harvested on the 7th day due to 60-80% cell viability throughout the entire
transfection period. Once the cells were harvested, the cell pellet was
separated from the supernatant and discarded. Supernatants are stored at 20ºC until protein purification.

Protein Purification
Supernatants were processed one of two ways: By normal flow filter
concentration prior to column purification or just column purification. At times,
if supernatant volumes surpassed a certain volume, the flow filter
concentration is used to concentrate the supernatants prior to loading on the
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AKTA Avant liquid chromatography system. A collection of supernatants, 300
mL volume maximum, were thawed and loaded into the protein concentrator.
A specific size exclusion membrane is used that only allows protein sizes up to
the molecular weight of the αDEC-205:OVA-ORG antibody to pass. The
concentrated supernatant was then collected into a secondary stationed 50
mL test tube for column purification on the AKTA Avant. All larger extraneous
protein is prevented from passing and maintained in the protein concentrator.
If that step was not warranted and was by passed, then supernatants
were purified using the AKTA Avant liquid chromatography system as per
manufacturer’s instructions (GE Healthcare Life Sciences). The supernatant
was streamed over a protein G column that contains bound Fc-receptors that
bind specifically to the protein of interest. Immediately after, a wash buffer was
ran over the protein G column to ensure the extraneous protein was washed
off the column and out of the machine. A second buffer containing competing
ligands was ran over the protein G column and the ligands bind to the Fc
receptors, outcompeting the protein of interest. The bound protein was eluted
off the column and into waiting micro-centrifuge tubes. A sudden spike in
protein concentration, represented as peaks on the AKTA Avant’s display
screen, alert to the presence of eluted protein in micro-centrifuge test tubes.
Fraction samples collected at various time points during the purification
process, such as prior to supernatant loading into the AKTA Avant,
supernatant (flow through) run-off once ran over the protein G column, wash
cycle run-off, and finally a sample of from the final purified eluate (Figure 8).
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These fraction samples were ran on a sodium dodecyl sulfate (SDS)
polyacrylamide (PAGE) gel and western blot to confirm purity of protein,
molecular weight of protein, and if any protein was lost throughout the
procedure. After protein purification confirmation, the newly purified protein’s
concentration was analyzed via Nano Drop. The protein was aliquoted into
working stock solutions and stored at 4ºC until further use.

Dendritic Cell Binding Assay
DC binding assays were performed to determine if the variant αDEC205:OVA antibodies, after modification, were capable of targeting and binding
to the DEC-205 receptor found on DCs after modification. JAWS II DCs were
aliquoted into FACS test tubes at 1 x 106/mL. Instantly, 5 ug/mL of purified wild
type and variant αDEC-205 antibodies were added to respective FACs test
tubes. The DC-antibody mixtures were cultured for 30 min. at room
temperature; this allows time for the antibodies to target the DEC-205
endocytic receptor. After the 30 min. incubation, DCs were washed twice
more. Afterwards, the FACs test tubes containing the wild type and variant
αDEC-205:OVA antibodies were stained with a rat-α-mouse IgG-PE antibody
for 1hr at 4ºC. This antibody only detects the αDEC-205:OVA antibody
attached to the DEC-205 receptor on the DC surface. Any αDEC-205:OVA
antibody not bound to the DEC-205 receptor was washed away after the
staining incubation in subsequent washes. DCs were then immediately
analyzed on the BD LSRII Flow Cytometer. The rat-α-mouse IgG-PE staining
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antibody allows for fluorescence intensity quantitation based on antibody
targeting capacity to the DEC205 receptor.

Immunization and Splenocyte Isolation Procedure
Immunizations to the 16 HLA-DR4 mice were performed using a 27’’
gauge needle for subcutaneous injections to the left hind flank. Immunizations
occur at the BSL-2 trailer at Peckham Farm on the University of Rhode
Island’s Kingston Campus. Immunizations and splenocyte culturing
procedures were followed according to a previously described protocol
(Bonifaz et al. 2004) with minor procedural adjustments.
16 HLA-DRB1*0401 mice are immunized on Day 0 and after a 7-day
time period mice were anesthetized with isoflurane (inhalant) via an oxygen
chamber and then euthanized with Ketamine (100µl/mouse). After euthanasia,
spleens were immediately harvested, put on ice, and transported back to
URI’s Feinstein Providence Campus (Bonifaz et al. 2004). Once back at the
lab, the splenocyte isolation procedure begins.
Splenocytes were isolated from their tissue matrix via maceration of
spleens over a 40µm nylon mesh filter that sits atop a 50 mL test tube. This is
performed for each respective immunization condition. Resulting splenocytes
are not pooled together and remain in their respective 50 mL collection test
tube. Afterwards, the filters atop of the 50 mL collection test tube were washed
with 10 mL RPMI-1640 culture media to displace residual splenocytes. A
Cellometer is then used to count the number of living splenocytes there are
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per milliliter of solution. Trypan blue, a viability dye exclusion method is used
to identify live and dead cells (Tran et al. 2011). Trypan blue was added to an
aliquot of cells and then loaded onto a counting chamber specific to the
Cellometer, which then determines the live cell concentration and viability of
the splenocyte samples. Splenocytes were separated according to number
requirements for each immunogenicity assay. Both memory response
immunogenicity assays, a T cell proliferation assay and a Murine (Mu)Interferon-gamma (IFN-γ) enzyme-linked immunospot assay (ELISpot), were
used to detect splenocyte pro-inflammatory tendencies observed from antigen
re-stimulation (Desombere et al. 2004, Desombere et al. 2005).
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Table 3. HLA-DRB1*0401 mice immunization
conditions.
Group ID Mouse ID

A

B

C

D

E

F

G

H

A1
A2
B1
B2
C1
C2
D1
D2
E1
E2
F1
F2
G1
G2
H1
H2

Immunization
Conditions
Negative CTL (PBS)
Antibody CTL
(αDEC:OVA-ORG)
αDEC:OVA + CD40
αISO:OVA + CD40
Adjuvant CTL (CD40)
αDEC:OVA-HC54-MOD1
(MUT1)
αDEC:OVA_VH77-MOD1
(MUT2)
αDEC:OVA_VH77-MOD2
(MUT3)
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Ex vivo T cell proliferation assay
Splenocytes were resuspended in prewarmed PBS/0.1% Fetal Bovine
Serum (FBS) at a final concentration of 1 x 107 cells/mL. CFSE labeling (1µM)
was performed per manufacturer’s instructions (Life Technologies) prior to
culture. Splenocyte containing FACs test tubes receive 1µL of the 1µM CFSE
solution and were incubated for 10 min. at 37ºC. With the addition of ice-cold
culture media at five times the volume, the CFSE staining process was
quenched. Immediately following, splenocytes were incubated for 5 min. in an
ice bath. After splenocytes are washed three times, they were plated in a 48well flat-bottomed plate at 1 x 106 cells/0.5 mL. Prior to 72hr 37ºC incubation,
splenocytes were re-stimulated with ovalbumin at 500µg/mL. Ovalbumin
antigen re-stimulation is done to identify if splenocytes can recall antigenspecific T cell response due to initial immunizations with ovalbumin (Bonifaz et
al. 2004).
Following the 72hr incubation, splenocytes were harvested and stained
with fluorophore-conjugated antibodies (Table 2) for 1hr at 4ºC. After the 1hr
incubation, excess staining antibody was removed with splenocyte washing.
Splenocytes were then analyzed for T cell proliferation on the BD LSRII Flow
Cytometer. For this particular experiment, CD3+CD4+ T helper cells and
CD3+CD8+ Cytotoxic T cells were identified amongst the splenic population
and measured for percent T cell proliferation. Of particular interest is the
percent T cell proliferative responses of the αDEC-205:OVA-ORG antibody
immunized splenocyte responses to ovalbumin re-stimulation in comparison to
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the proliferative responses of the variant αDEC-205:OVA antibody immunized
splenocytes.

Ex vivo ELISpot assay
The capture and detection antibodies were supplied by MABTECH and
the ELISpot assay protocol was followed per manufacturer’s kit instructions
(Ngai et al. 2007). Splenocytes were loaded into Mu-IFN-γ 96-well roundbottomed plates pre-coated with an IFN-γ binding capture antibody. Plates
were then washed four times with 1x Phosphate Buffer Saline (PBS) and
loaded with 150 uL RPMI-1640 culture media for 30 min. at room temperature.
Following this, splenocytes were then plated at 250,000cells/well. All
stimulations were performed in triplicate; the negative controls were
represented with 6 wells each comprising splenocytes and media alone.
Afterwards, each well was re-stimulated, if necessary according to the
experimental plan. Antigen stimulations included OVA class I (257-264) and OVA
class II (323-339) peptides (10 µg/mL) as per the previously described protocol by
Bonifaz et al. (2004) (Table 4). The Class I and II OVA peptides were
predicted to bind to the DR4 allele and have shown to be capable of detecting
and inducing activation and proliferation of CD8+ Cytotoxic T cells and CD4+ T
helper cells, respectively (Bonifaz et al. 2004, Sun et al. 2010). Concanavalin
A (CON A) was added to the positive control wells only (2 µg/mL). CON A is
normally used as a positive control treatment condition because it readily
triggers T cell activation and proliferation (Palacios, 1982). Plates were then

44

placed in a 37ºC incubator for 48 hr.
After the 48hr incubation, plates were washed five times and IFN-γ
production was detected according to the MABTECH development protocol.
The biotinylated-detection antibody (R4-6A2-biotin) was then diluted to 1ug/mL
in PBS containing 0.5% FBS and 100µL was added to each well. Following
this step, plates were incubated for 2hr at room temperature. After incubation,
plates were re-washed and 100 µL Streptavidin-Horseradish Peroxidase
(HRP) conjugate (diluted 1:1000) was added to each well. Plates were then
incubated at room temperature for 1hr. Following incubation, to visually
observe if IFN-γ secretion occurred due to antigen re-stimulation, plates were
washed and then loaded with 100µL TMB substrate per well. The plates were
immediately left to develop for a maximum of 10 min. at room temperature,
until distinct blue spots emerged. The colorimetric TMB substrate forms an
insoluble precipitate when catalyzed by the Streptavidin-HRP enzyme and
acts as a visible representation of a single activated cell secreting the IFN-γ
cytokine (MABTECH). Each plate’s color development was stopped after
extensive plate rinsing with tap water. Plates were left to dry overnight and
inspected for spots the following day, utilizing the ELISpot Reader (Cellular
Technologies Limited, Cleveland, OH).
In general, a positive T-cell response was defined by a significantly
elevated spot count in antigen-stimulated wells over the non-stimulated media
only-control (negative-control), usually, 50 spot forming units above
background was considered a positive response (Dittrich et al. 2012). The
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data generated by the ELISpot Counter was then compiled into an excel
spreadsheet. Each triplicate’s spot data, not including the negative controls,
was added together and then averaged, resulting in one value representative
of the immunization condition’s positive control and antigen stimulated
samples. As for the negative controls, all 6 wells per respective immunization
condition were added together and then averaged. The resulting negative
control values represent the background “noise” of the assay. Each
immunization condition’s negative control values were then subtracted from
their respective antigen stimulated averaged sample values. The newly
generated averaged data was then normalized to 1 million cells. The resulting
spot count data now represents an actual IFN-γ response due to antigenic
peptide re-stimulation.

Table 4. OVA Class I and Class II peptide sequences.
Specific peptide sequences were found within the whole
protein, Ovalbumin, which was used in the Mu-ELISpot
IFN-γ assay as a method of antigen re-stimulation.
OVA Peptide ID

Sequence

Class I (257-264)

SIINFEKL

Class II (323-339)

ISQAVHAAHAEINEAGR

Flow Cytometry
The BD LSRII Flow Cytometer identifies and functionally characterizes
various cellular population subsets (BDBiosciences). Prior to all experiments,
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compensation must be performed to inform the machine of each antibody
stain’s fluorophore fluorescence intensity (FI) and to confirm each
fluorophore’s FI matches perfectly with the specified cell marker-antibody stain
used. Compensation is also necessary to perform when multiple fluorophores
are used per assay and per cell because it also addresses the issue of
spillover, which is the physical overlap of emission spectra (BD Biosciences).
Filters are in place in the machine to try and prevent as much spillover of
fluorescence spectra as possible, however, most fluorophores emit over a
broad range of wavelength so a compensation process is required to subtract
the fluorescence spectral spillover from other channels (BD Bioscience). Data,
for all samples, was acquired on the same day using the BD LSRII Flow
Cytometer to assure consistency among samples. Once sample acquisition
was complete, samples are analyzed with BD’s FacsDiva Software V8.0 and
Tree Star’s FlowJo Analysis Software V7.6.5.

Statistical Analyses
Data generated from both ex vivo memory immune response assays is
taken and compiled into an excel spreadsheet. Analyses are performed per
experiment using the Mann-Whitney U test in the GraphPad Prism 6 software,
a non-parametric t-test that measures for the significant difference between
two groups of independent samples (Doerge et al. 2009). This test is normally
used when the data set does not meet the requirements for a parametric t-test,
such as the data set is not normally distributed (Doerge et al. 2009). Each
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sample condition’s data set was tested for normal distribution using the
Shapiro-Wilk frequency distribution test. All data sets were shown to not have
normal distribution (not shown). Both data sets for the two conditions that were
compared were compiled together and then ranked from lowest to highest. If
identical values were present within the data set, each of the values respective
ranks are added together and then averaged to break the tie (Doerge et al.
2009). From now on, only the ranking values are used rather than the
measured data value. Therefore, the ranks are separated back into their
respective sample conditions and the sum is taken. Each sample condition’s
rank total is then used to observe the differences between the two conditions.
Generally, if there is a systematic difference, the sample condition receiving
the significantly greater immune response will tend to have the higher-ranking
values, while the other sample condition will tend towards the lowering ranking
values (Doerge et al. 2009). However, if both sample conditions generate a
similar immune response then both high and low ranking values are distributed
fairly amongst the two sample conditions, and both rank totals will be fairly
similar (Doerge et al. 2009).
One of the statistics generated from the ranked data set is a p-value.
The p-value is a probability and measures the strength of evidence against the
null hypothesis. The assumption being the null hypothesis is true (Stills, 2005).
Thus, it measures the likelihood of significance and whether the difference
observed between the two data sets likely is to occur by random chance
(Stills, 2005). All Mann-Whitney-U statistical analyses performed for these
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assays are one-tailed with a 95% confidence interval, therefore, the p-value
significance level threshold is set at 0.05. Any p-value score that is lower than
the 0.05 significance level threshold is considered significant and the null
hypothesis can be rejected. Generally, the lower the p-value score, the more
significant and the greater the difference observed between two sample
conditions (Stills, 2005).
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CHAPTER 4

FINDINGS
In silico Analyses
In order to first create a de-tolerized antibody, tolerogenic signals must
be located within the αDEC-205 antibody’s sequence. Specific amino acids
within the Tregitope sequence, at key positions, were selected for
modification. The aim was to perform the least amount of substitutions as
possible to minimize the likelihood of disruption to structure and function of the
antibody sequences, as well as, reduce binding potential to the respective
HLA allele (Moise et al. 2012). Therefore, the entire EpiMatrix suite of tools
were used to identify T cell epitopes, potentially regulatory in nature, based on
criterion defined in the epitope-mapping algorithms and suggest and substitute
in key amino acid replacements in order to reduce the binding potential of the
tolerogenic signals to the HLA allele (De Groot et al. 2008).
EpiMatrix Cluster report analyses showed EpiMatrix z-scores for each
of the 8 alleles; however, only the DR4 allele was of interest due to future in
vivo immunizations taking place in HLA-DR4 mice (Tables 5-9). In total, only
two out of the six Tregitope sequences within the αDEC-205 antibody’s
sequence were targeted for modification (VH77 & HC54) based on previous
research performed by De Groot et al. 2008 indicating that VH77
(unpublished) and HC54 Tregitope sequences are the most immunogenic out
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of the six Tregitopes. These two Tregitope sequences comprise the most
potential for driving this tolerogenic immune response based on prior research
showing ex vivo expansion of CD4+CD25+FoxP3+ T cells when Tregitopes are
used as stimulation conditions for PBMCs (De Groot et al 2008, De Groot et
al. 2013, Cousens et al. 2013). Tregitope sequences HC54 and VH77 were
defined as 22 and 23 amino acid length sequences, respectively (Table 10).
Both HC54 and VH77 Tregitope sequences, with respect to the HLADR4 allele, contain four hits in total, with three of the four hits in at least the
top 5th percentile for peptides likely to bind to the DR4 allele for each
sequence (Tables 5,7). This suggests there are three potentially regulatory
sequence frames within both Tregitope sequences (HC54 and VH77) that are
predicted to bind to the HLA-DR4 allele. The EpiMatrix Cluster reports showed
Tregitope sequences, αDEC-205:OVA-HC54-ORG and αDEC-205:OVAVH77-ORG, have 2.5 Epibars and 4 Epibars when compared against the
panel of 8 class II alleles, respectively (Tables 5, 7), suggesting the presence
of promiscuous alleles, which further suggests that these sequence frames are
potentially regulatory in nature and are predicted to bind to the DR4 allele (De
Groot et al. 2008). More specifically, the αDEC-205:OVA-HC54-ORG (original)
sequence contains 1 top 1% hit and 2-top 5% hits (Table 5). The sequence
does contain a top 10% hit, which is considered to be non-significant and least
likely to bind to the DR4 allele. The Tregitope αDEC-205:OVA-VH77-ORG
(original) sequence (VH77-MOD1) contains 1 top 1% hit, 2-top 5% hits, and 1
top 10% hit (non-significant) (Table 7).
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Modification to the (22 amino acid-length) Tregitope αDEC-205:OVAHC54-MOD1 (HC54-MOD1) sequence involved the replacement of amino
acids, leucine (position 4 & 11) and tyrosine (position 9), with all alanine amino
acids. The resulting modifications to the HC54-MOD1 Tregitope sequence
decreased the possible number of sequence frames likely to bind to the DR4
allele, from three sequence frames to one (Table 10). The EpiMatrix z-score
also decreased after subsequent modification, however, the single retained
top 5% hit sequence frame suggests this sequence frame is still predicted to
have a significant chance of binding to the DR4 allele, which could potentially
inhibit effector, pro-inflammatory immune responses if presented and activates
T cells (Table 6).
In terms of the (23 amino acid-length) Tregitope VH77-ORG sequence,
substitution of leucine (position 12) to alanine resulted in the VH77-MOD1
Tregitope sequence and further substitution of tyrosine (position 6) to alanine
resulted in the VH77-MOD2 Tregitope sequence. After modification to the
VH77-ORG Tregitope sequence, the number of 9-mer frames predicted to
bind to the DR4 allele decreased, similar to the HC54-ORG Tregitope
sequence, from three sequence frames (ORG) to one top 1% hit-sequence
frame within the VH77-MOD1 Tregitope sequence and zero frames in the
VH77-MOD2 Tregitope sequence (Table 7-9). After modification, the EpiMatrix
z-scores for all sequence frames relevant to the DR4 allele also decreased,
similar to the HC54-ORG modification. However, in regards to the VH77MOD1 Tregitope sequence, there is still one sequence frame, after
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modification, still predicted to bind to the DR4 allele. Though the EpiMatrix zscores decreased after modification, this sequence frame is still considered a
top 1% hit and predicted to have an extremely likely chance of binding to the
DR4 allele. The resulting VH77-MOD2, after modification, did not retain any
sequence frames predicted to bind to the DR4 allele.

EpiMatrix Cluster Detail Report
File: STEINMAN_DEC205_MODS Sequence: MUDEC205_CH_54_ORG Cluster: 54
November 04, 2011 (Epx Ver. 1.2)
Frame
Start
54
55
56
57
58
59
60
61
62
63
64
65
66
67

AA Sequence
PAVLQSDLY
AVLQSDLYT
VLQSDLYTL
LQSDLYTLS
QSDLYTLSS
SDLYTLSSS
DLYTLSSSV
LYTLSSSVT
YTLSSSVTV
TLSSSVTVP
LSSSVTVPS
SSSVTVPSS
SSVTVPSST
SVTVPSSTW

Frame
Stop
62
63
64
65
66
67
68
69
70
71
72
73
74
75

Hydrophobicity
0.32
0.42
0.64
0.09
-0.42
-0.12
0.43
0.74
0.79
0.76
0.74
0.23
0.24
0.23

Summarized Results (04-NOV-2011)
Maximum Single Z score
Sum of Significant Z scores
Count of Significant Z Scores
Total Assessments Performed: 112
Scores Adjusted for Tregitope:

DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101
Z-Score
Z-Score
Z-Score
Z-Score
Z-Score
Z-Score
0.45
-0.19
-0.06
-0.77
-1.45
-0.43
-0.01
-0.64
0.93
-0.04
-0.12
0.49
0.3
1.38
0.02
1.07
0.36
0.86
1.69
2.13
1.79
0.33
0.83
-0.08
0.51
-0.52
1.22
-0.32
0.17
0.8
-1.33
-0.34
-0.84
-1.05
0.28
-0.14
0.96
-0.08
0.65
1.86
-0.02
-0.3
1.87
0.22
1.55
1.84
1.04
1.25
2.7
2.15
2.29
3.23
1.32
1.52
-0.12
0.02
0.42
0.3
-0.55
-0.59
1.86
2.25
2.33
1.33
1.24
1.38
0.39
0.34
0.73
-0.36
0.34
1.04
0.25
-1.19
-0.1
0.71
-0.39
-0.79
-0.15
-0.23
-0.33
1.21
-1.11
-0.61

DRB1*1301 DRB1*1501
Z-Score
Z-Score
-0.48
-0.49
0.24
1.07
0.89
1.48
1.01
0.98
-0.13
-0.01
0.89
0.68
0.64
1.11
0.34
1.8
1.77
2.02
-0.31
-1.27
1.88
1.39
0.64
0.21
-0.46
0.27
-0.11
0.28

Hits
0
0
0
3
0
0
1
3
6
0
4
0
0
0

DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501
Total
2.7
2.25
2.33
3.23
1.32
1.52
1.88
2.02
-8.12
6.54
6.42
6.93
0
0
3.65
3.82
35.48
4
3
3
3
0
0
2
2
17
Hydrophobicity: 0.30
EpiMatrix Score: 23.94
EpiMatrix Score (w/o flanks): 23.94
-EpiMatrix Score: 23.94
EpiMatrix Score (w/o flanks): 23.94
Top 10% *

Top 5%

I-AB
Z-Score
!0.5
!1.05
!0.04
1.09
0.6
!1.06
0.56
0.34
1.85
0.49
1.12
0.4
0.77
0.6

I-AD
Z-Score
0.76
0.26
0.18
!0.45
0.65
0.76
0.23
1.01
1.35
!0.35
0.18
2.25
1.81
!0.03

I-ED
Z-Score
1.16
!1.06
!0.84
0.44
!0.82
!1.84
!2.42
!0.86
!0.59
0.21
!2.04
!1.59
!1.68
!1.82

1.85
1.85
1

2.25
4.06
2

1.16
!!
0

Top 1%

Table 5. The αDEC-205:OVA-HC54-ORG EpiMatrix Cluster
Report analysis. Significant EpiMatrix z-scores ≥ 1.64 (hits), for all
8 alleles, are highlighted in the medium blue and dark-blue colors.
An EpiMatrix z-score indicates potential for that particular 9mer
frame sequence to bind to a given HLA allele. There are three hits
relevant to the DRB1*0401 allele and are predicted to bind, prior to
modification.
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EpiMatrix Cluster Detail Report
File: STEINMAN_DEC205_MODS Sequence: MUDEC205_CH_54_MOD1 Cluster: 54
November 04, 2011 (Epx Ver. 1.2)
Frame
Start
54
55
56
57
58
59
60
61
62
63
64
65
66
67

AA Sequence
PAVLQSDLY
AVLQSDLYT
VLQSDLYTG
LQSDLYTGS
QSDLYTGSS
SDLYTGSSS
DLYTGSSSV
LYTGSSSVT
YTGSSSVTV
TGSSSVTVP
GSSSVTVPS
SSSVTVPSS
SSVTVPSST
SVTVPSSTW

Frame
Stop
62
63
64
65
66
67
68
69
70
71
72
73
74
75

Hydrophobicity
0.32
0.42
0.18
-0.38
-0.89
-0.59
-0.03
0.28
0.32
0.29
0.28
0.23
0.24
0.23

Summarized Results (04-NOV-2011)
Maximum Single Z score
Sum of Significant Z scores
Count of Significant Z Scores
Total Assessments Performed: 112
Scores Adjusted for Tregitope:

DRB1*0101
Z-Score
0.45
-0.01
-0.03
1.35
0.21
-0.1
0.69
0.97
2.41
-0.65
0.74
0.39
0.25
-0.15

DRB1*0301
Z-Score
-0.19
-0.64
1.18
1.79
-0.58
-0.6
-0.35
0.26
1.86
-0.52
0.97
0.34
-1.19
-0.23

DRB1*0101 DRB1*0301
2.41
1.86
2.41
3.65
1
2
Hydrophobicity: 0.10
--

DRB1*0401
Z-Score
-0.06
0.93
0.23
1.46
0.46
0
0.39
0.99
2.02
-0.1
1.24
0.73
-0.1
-0.33

DRB1*0701
Z-Score
-0.77
-0.04
-0.32
-0.01
-0.41
-0.42
1.6
1.18
2.95
-0.22
0.22
-0.36
0.71
1.21

DRB1*0801
Z-Score
-1.45
-0.12
0.84
0.48
0.1
0.01
-0.3
0.03
1.02
-1.11
0.05
0.34
-0.39
-1.11

DRB1*0401 DRB1*0701 DRB1*0801
2.02
2.95
1.02
2.02
2.95
0
1
1
0
EpiMatrix Score: 1.24
EpiMatrix Score: 1.24

DRB1*1101
Z-Score
-0.43
0.49
1.09
-0.43
0.32
-0.4
-0.58
0.26
1.23
-1.13
0.23
1.04
-0.79
-0.61

DRB1*1301
Z-Score
-0.48
0.24
0.69
0.67
-1.42
0.64
0.37
-0.29
1.49
-0.84
0.62
0.64
-0.46
-0.11

DRB1*1501
Z-Score
-0.49
1.07
1.16
0.65
-0.3
0.68
0.85
1.43
1.74
-1.78
0.16
0.21
0.27
0.28

Hits
0
0
0
1
0
0
0
0
5
0
0
0
0
0

I-AB
Z-Score
!0.5
!1.05
0.07
1.09
0.63
!0.17
0.56
0.46
2.27
0.61
0.78
0.4
0.77
0.6

I-AD
Z-Score
0.76
0.26
1.14
!1.04
0.41
0.32
!0.1
0.99
1.68
0.11
!0.35
2.25
1.81
!0.03

I-ED
Z-Score
1.16
!1.06
!0.74
!0.21
!0.6
!1.1
!1.95
!1.4
!0.91
0.22
!2.73
!1.59
!1.68
!1.82

2.27
2.27
1

2.25
5.74
3

1.16
!!
0

DRB1*1101 DRB1*1301 DRB1*1501
Total
1.23
1.49
1.74
-0
0
1.74
12.77
0
0
1
6
EpiMatrix Score (w/o flanks): 1.24
EpiMatrix Score (w/o flanks): 1.24
Top 10% *

Top 5%

Top 1%

Table 6. The αDEC-205:OVA-CH54-MOD1 EpiMatrix Cluster
Report analysis. Significant EpiMatrix z-scores ≥ 1.64 (hits), for all
8 alleles, are highlighted in the medium blue and dark-blue colors.
An EpiMatrix z-score indicates potential for that particular 9mer
frame sequence to bind to a given HLA allele. After modification,
there is a single 9mer sequence frame considered a top 5% hit
that is predicted to have a significant chance of binding to the
DRB1*0401 allele.

EpiMatrix Cluster Detail Report
File: STEINMAN_DEC205_MODS Sequence: MUDEC205_VH_77_ORG Cluster: 77
November 04, 2011 (Epx Ver. 1.2)
Frame
Start
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91

AA Sequence
TQNILYLQM
QNILYLQMN
NILYLQMNS
ILYLQMNSL
LYLQMNSLR
YLQMNSLRA
LQMNSLRAE
QMNSLRAED
MNSLRAEDT
NSLRAEDTA
SLRAEDTAI
LRAEDTAIY
RAEDTAIYY
AEDTAIYYC
EDTAIYYCA

Frame
Stop
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99

Hydrophobicity
0.17
-0.14
0.16
0.97
-0.03
-0.26
-0.5
-1.31
-1
-1.01
-0.12
-0.18
-0.74
0.03
0.03

Summarized Results (04-NOV-2011)
Maximum Single Z score
Sum of Significant Z scores
Count of Significant Z Scores
Total Assessments Performed: 120
Scores Adjusted for Tregitope:

DRB1*0101
Z-Score
0.73
0.23
-0.44
1.69
1.92
3.3
0.03
-0.09
2.01
-0.93
0.04
1.23
-0.8
-2.15
-0.42

DRB1*0301
Z-Score
-0.43
-0.3
-0.62
1.38
2.33
2.01
1.72
0.15
0.53
-1.69
0.87
1.7
1.12
-3.06
-1.25

DRB1*0101 DRB1*0301
3.3
2.33
8.92
7.76
4
4
Hydrophobicity: -0.06
--

DRB1*0401
Z-Score
-0.04
-0.1
-0.26
1.21
1.89
3.41
0.08
-0.98
1.62
-1.57
0.44
1.66
-0.21
-1.99
-0.71

DRB1*0701
Z-Score
0.52
0.02
-0.67
1.92
1.08
2.9
0.03
-0.19
1.66
-1.3
0.43
-0.12
-1.74
-0.91
-0.56

DRB1*0801
Z-Score
-1.69
1.14
0.71
1.29
2.02
2.23
1.89
0.93
1.39
-1.33
-0.13
-0.47
-1.64
-1.81
-1.29

DRB1*0401 DRB1*0701 DRB1*0801
3.41
2.9
2.23
6.96
6.47
6.14
3
3
3
EpiMatrix Score: 38.59
EpiMatrix Score: -0.05

DRB1*1101
Z-Score
-0.12
0.63
0.44
1.56
1.57
3.43
1.52
0.35
1.52
-0.87
-1.17
0.85
-1.8
-2.48
-1.02

DRB1*1301
Z-Score
0.08
-1.26
-0.22
0.81
2.91
1.97
1.24
0.04
0.29
-1.12
0.84
1.67
-0.01
-2.32
-1.37

DRB1*1501
Z-Score
0.54
0.54
0.36
1.61
1.9
2.82
0.33
-0.82
1.42
-1.51
1.12
-0.25
-0.83
-1.43
-0.29

Hits
0
0
0
2
6
8
2
0
2
0
0
3
0
0
0

DRB1*1101 DRB1*1301 DRB1*1501
Total
3.43
2.91
2.82
-3.43
6.55
4.71
50.94
1
3
2
23
EpiMatrix Score (w/o flanks): 38.59
EpiMatrix Score (w/o flanks): -0.05
Top 10% *

Top 5%

I-AB
Z-Score
0.23
'0.63
'1.71
'0.89
'1.2
1.6
0.72
0.26
1.15
'0.92
'0.79
1.36
'0.56
1.45
0.81

I-AD
Z-Score
1.42
0.53
'0.17
0.69
'1.46
1.42
'0.6
'1.15
1.21
'0.8
'0.65
0.38
1.13
'0.26
1.27

I-ED
Z-Score
'0.24
0.56
'1.07
'0.36
1.57
'1.44
'0.33
0.68
'0.02
'0.11
'0.41
1.15
'0.13
'0.96
'0.32

1.6
''
0

1.42
''
0

1.57
''
0

Top 1%

Table 7. The αDEC-205:OVA-VH77-ORG EpiMatrix Cluster Report
analysis. EpiMatrix z-scores ≥ 1.64 (hits), for all 8 alleles, are
highlighted in the medium blue and dark-blue colors. An EpiMatrix zscore indicates potential for that particular 9mer frame sequence to
bind to a given HLA allele. There are three 9mer frame sequences
predicted to bind to the HLA-DRB1*0401 allele. The frames
highlighted in green are the conserved IgG sequences and are
chosen for modification.
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EpiMatrix Cluster Detail Report
File: STEINMAN_DEC205_MODS Sequence: MUDEC205_VH_77_MOD1 Cluster: 77
November 04, 2011 (Epx Ver. 1.2)
Frame
Start
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91

AA Sequence
TQNILYLQM
QNILYLQMN
NILYLQMNS
ILYLQMNSG
LYLQMNSGR
YLQMNSGRA
LQMNSGRAE
QMNSGRAED
MNSGRAEDT
NSGRAEDTA
SGRAEDTAI
GRAEDTAIY
RAEDTAIYY
AEDTAIYYC
EDTAIYYCA

Frame
Stop
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99

Hydrophobicity
0.17
-0.14
0.16
0.5
-0.5
-0.72
-0.97
-1.78
-1.47
-1.48
-0.59
-0.64
-0.74
0.03
0.03

Summarized Results (04-NOV-2011)
Maximum Single Z score
Sum of Significant Z scores
Count of Significant Z Scores
Total Assessments Performed: 120
Scores Adjusted for Tregitope:

DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101
Z-Score
Z-Score
Z-Score
Z-Score
Z-Score
Z-Score
0.73
-0.43
-0.04
0.52
-1.69
-0.12
0.23
-0.3
-0.1
0.02
1.14
0.63
-0.44
-0.62
-0.26
-0.67
0.71
0.44
1.36
1.18
1.43
0.53
1.77
1.78
1.58
1.99
1.56
0.74
1.66
1.22
2.99
1.95
2.64
2.81
2.15
2.96
1.26
1.46
0.92
0.67
1.62
1.26
-0.36
-0.12
-1.24
-0.46
0.65
0.07
1.11
0.58
1.05
0.99
0.37
0.52
-1.21
-1.98
-1.85
-1.58
-1.63
-1.16
-0.49
0.34
-0.07
-0.09
-0.68
-1.71
0.1
0.41
0.57
-1.23
-1.65
-0.3
-0.8
1.12
-0.21
-1.74
-1.64
-1.8
-2.15
-3.06
-1.99
-0.91
-1.81
-2.48
-0.42
-1.25
-0.71
-0.56
-1.29
-1.02

DRB1*1301 DRB1*1501
Z-Score
Z-Score
0.08
0.54
-1.26
0.54
-0.22
0.36
0.61
1.29
2.57
1.57
0.68
2.52
0.99
0.34
-0.23
-1.08
-0.34
1.05
-1.41
-1.78
0.32
0.61
0.41
-1.48
-0.01
-0.83
-2.32
-1.43
-1.37
-0.29

Hits
0
0
0
2
3
7
0
0
0
0
0
0
0
0
0

I-AB
Z-Score
0.23
'0.63
'1.71
'0.78
'1.2
1.64
1.61
0.26
1.27
'0.5
'0.67
1.01
'0.56
1.45
0.81

I-AD
Z-Score
1.42
0.53
'0.17
1.65
'2.06
1.18
'1.04
'1.47
1.19
'0.47
'0.19
'0.15
1.13
'0.26
1.27

I-ED
Z-Score
'0.24
0.56
'1.07
'0.25
0.91
'1.21
0.42
1.15
'0.56
'0.43
'0.39
0.46
'0.13
'0.96
'0.32

1.64
1.64
0

1.65
1.65
1

1.15
''
0

DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501
Total
2.99
1.99
2.64
2.81
2.15
2.96
2.57
2.52
-2.99
3.94
2.64
2.81
5.58
4.74
2.57
2.52
27.79
1
2
1
1
3
2
1
1
12
Hydrophobicity: -0.24
EpiMatrix Score: 15.45
EpiMatrix Score (w/o flanks): 15.45
-EpiMatrix Score: 15.45
EpiMatrix Score (w/o flanks): 15.45
Top 10% *

Top 5%

Top 1%

Table 8. The αDEC-205:OVA-VH77-MOD1 EpiMatrix Cluster Report
analysis. EpiMatrix z-scores ≥ 1.64 (hits), for all 8 alleles, are
highlighted in the medium blue and dark-blue colors. An EpiMatrix zscore indicates potential for that particular 9mer frame sequence to
bind to a given HLA allele. After modification, there is a single-9mer
frame sequence considered a top 1% hit that is predicted to bind to
the HLA-DRB1*0401 allele.

EpiMatrix Cluster Detail Report
File: STEINMAN_DEC205_MODS Sequence: MUDEC205_VH_77_MOD2 Cluster: 77
November 04, 2011 (Epx Ver. 1.2)
Frame
Start
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91

AA Sequence
TQNILALQM
QNILALQMN
NILALQMNS
ILALQMNSG
LALQMNSGR
ALQMNSGRA
LQMNSGRAE
QMNSGRAED
MNSGRAEDT
NSGRAEDTA
SGRAEDTAI
GRAEDTAIY
RAEDTAIYY
AEDTAIYYC
EDTAIYYCA

Frame
Stop
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99

Hydrophobicity
0.51
0.2
0.5
0.84
-0.16
-0.38
-0.97
-1.78
-1.47
-1.48
-0.59
-0.64
-0.74
0.03
0.03

Summarized Results (04-NOV-2011)
Maximum Single Z score
Sum of Significant Z scores
Count of Significant Z Scores
Total Assessments Performed: 120
Scores Adjusted for Tregitope:

DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501
Z-Score
Z-Score
Z-Score
Z-Score
Z-Score
Z-Score
Z-Score
Z-Score
1.16
0.43
1.03
0.98
-0.8
0.75
0.92
0.94
0.16
-0.37
-0.17
-0.05
1.06
0.56
-1.33
0.47
0.46
0.56
0.58
-0.21
0.67
0.78
-0.4
0.51
1.5
1.33
1.57
0.68
1.92
1.94
0.76
1.43
1.32
1.72
1.3
0.48
1.38
0.95
2.31
1.31
1.53
0.89
1.22
1.37
0.62
1.46
-0.36
1.51
1.26
1.46
0.92
0.67
1.62
1.26
0.99
0.34
-0.36
-0.12
-1.24
-0.46
0.65
0.07
-0.23
-1.08
1.11
0.58
1.05
0.99
0.37
0.52
-0.34
1.05
-1.21
-1.98
-1.85
-1.58
-1.63
-1.16
-1.41
-1.78
-0.49
0.34
-0.07
-0.09
-0.68
-1.71
0.32
0.61
0.1
0.41
0.57
-1.23
-1.65
-0.3
0.41
-1.48
-0.8
1.12
-0.21
-1.74
-1.64
-1.8
-0.01
-0.83
-2.15
-3.06
-1.99
-0.91
-1.81
-2.48
-2.32
-1.43
-0.42
-1.25
-0.71
-0.56
-1.29
-1.02
-1.37
-0.29

Hits
0
0
0
2
2
0
0
0
0
0
0
0
0
0
0

DRB1*0101 DRB1*0301 DRB1*0401 DRB1*0701 DRB1*0801 DRB1*1101 DRB1*1301 DRB1*1501
Total
1.53
1.72
1.57
1.37
1.92
1.94
2.31
1.51
-0
1.72
0
0
1.92
1.94
2.31
0
7.89
0
1
0
0
1
1
1
0
4
Hydrophobicity: -0.11
EpiMatrix Score: -4.47
EpiMatrix Score (w/o flanks): -4.47
-EpiMatrix Score: -4.47
EpiMatrix Score (w/o flanks): -4.47
Top 10% *

Top 5%

I-AB
I-AD
I-ED
Z-Score Z-Score Z-Score
0.89
2.01
'0.29
'0.63
'0.14
0.27
'0.87
0.37
'1.22
'0.46
1.74
'0.03
'1.26
'2.25
0.52
0.4
0.82
'1.73
1.61
'1.04
0.42
0.26
'1.47
1.15
1.27
1.19
'0.56
'0.5
'0.47
'0.43
'0.67
'0.19
'0.39
1.01
'0.15
0.46
'0.56
1.13
'0.13
1.45
'0.26
'0.96
0.81
1.27
'0.32

1.61
''
0

2.01
3.75
2

1.15
''
0

Top 1%

Table 9. The αDEC-205:OVA-VH77-MOD2 EpiMatrix Cluster
Report analysis. Significant EpiMatrix z-scores ≥ 1.64 (hits), for all
8 alleles, if present, are highlighted in the medium blue and darkblue colors. An EpiMatrix z-score indicates potential for that
particular 9mer frame sequence to bind to a given HLA allele.
There are not any 9mer frame sequences predicted to bind to the
DRB1*0401 allele, after modification.
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Table 10. Potential Tregitope sequences selected for modification. Nonmodified and modified predicted Tregitope sequences showing the number
of epitope sequence frames predicted to bind to the HLA-DRB1*0401
allele. The table also shows which sequences were successfully expressed
into recombinant protein.
Antibodies

Cluster
Address

Cluster Sequence

HLADRB1*0401
EpiMatrix Hits

Produced

αDEC-205:HC54ORG

54-75

PAVLQSDLYTLSSSVTVPSSTW

3

YES

αDEC-205:HC54MOD1

54-75

PAVAQSDLATASSSVTVPSSTW

1

YES

αDEC-205:HC54MOD2

54-75

PAVAQSDLATASQSVTVPSSTW

0

NO

αDEC-205:VH77ORG

77-99

TQNILYLQMNSLRAEDTAIYYCA

3

YES

αDEC-205:VH77MOD1

77-99

TQNILYLQMNSGRAEDTAIYYCA

1

YES

αDEC-205:VH77MOD2

77-99

TQNILALQMNSGRAEDTAIYYCA

0

YES

αDEC-205:VH77MOD3

77-99

TQNIGALQMNSGRAEDTAIYYCA

0

NO
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Protein Purification
In total, recombinant expression of six variant αDEC-205:OVA
antibodies was attempted, however only three of the six variant antibodies
were successfully expressed. The other three variant antibodies showed either
no or low expression levels, which suggested that the epitope modifications
performed were deleterious to the structure. Purified recombinant protein was
determined via gel electrophoresis analyses, which showed the presence of
strong bands at the predicted molecular weights for a single light (25 kD) and
a single heavy chain attached to ovalbumin (95 kD) (Ito et al. 1996, Janeway
et al. 2001, Sun et al. 2010). The resulting recombinant antibodies
successfully expressed were αDEC-205:OVA-HC54-MOD1, αDEC-205:OVAVH77-MOD1, and αDEC-205:OVA-VH77-MOD2 (Table 10).
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Load FT Wash Elute2 Load FT Wash Elute2
260
140
HC

100
70
50
40
35
25

LC

15
10
αDEC-205:OVA-ORG

αDEC-205:OVA-HC77-MOD1

Figure 8. A gel electrophoresis image showing the purity check points
taken during protein purification. A sample of protein supernatant is
taken prior to purification, during purification over protein G column,
wash through, and the final eluting of the concentrated sample’s heavy
and light chain. The expected molecular weight of a single heavy chain
attached to Ovalbumin is 95 kD. The molecular weight of a single light
chain is 25 kD.
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WT

Mut 3

Mut 1

Mut 4

260
140
100

HC

70
50
40
35
25
15

LC

10 = αDEC-205-ORG Mut 1= HC54-MOD1 Mut 3= HC77-MOD1
WT
Mut 4= HC77-MOD2
Figure 9. A gel electrophoresis image showing the production
of wild type and modified αDEC-205 antibodies.
Mut 1 Mut 2 Mut 3 Mut 4 Mut 5 Mut 6
260
140
100
70
50
40
35
25
15

HC
Protein G
LC

10
Mut 1= HC54-MOD1 Mut 2= HC54-MOD2 Mut 3= VH77-MOD1
Mut 4= VH77-MOD2 Mut 5= VH77-MOD3 Mut 6= VH77-HC54
Figure 10. A gel electrophoresis image showing the correct or partial
production of the variant αDEC-205:OVA antibodies. Mutant antibodies,
HC54-MOD1, VH77-MOD1, VH77-MOD2, were produced correctly during
transfection, where as, mutant antibodies HC54-MOD2, VH77-MOD3, and
VH77-HC54 were only partially produced due to lack of heavy chain
presence on the gel. .
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Dendritic Cell Binding Assay
Using the flow cytometer analysis software (BD FACs Diva V8.0) DC
subsets negative for the CD11c+ marker (DC lineage marker) were gated on to
establish the negative control DC population (Figure 11). Further selective
gating for the αIgG-FITc staining antibody was performed. Any DCs migrating
from the initial negative control population to the “CD11c+ αIgG-FITC+ ”
labeled quadrant indicates double positive DC staining (Figure 12). Migration
into the double positive quadrant further indicates αDEC-205:OVA antibodies
(ORG and variant) are present and targeting the DEC-205 receptor, within
their respective samples.
The negative control JAWS II DC population was not pulsed with any
antibody, but was stained with the αIgG-FITc antibody. However, 3.3% of the
CD11c+ DCs were shown to have positive staining for the αIgG-FITc antibody.
This suggests that the αIgG-FITc antibody is capable of non-specifically
binding to DCs. That non-specific binding percentage was then subtracted
from all resulting positive binding data. As for the DCs that were pulsed with
the αIso:OVA antibody, similar results to the negative control are observed.
Only 3.1% of the JAWS II CD11c+ DC total population are targeted by the nonspecific antibody and positively stained with the αIgG-FITc antibody (Figure
11).
The column graph (Figure 13) demonstrates that all three variant
antibodies (HC54-MOD1, VH77-MOD1, VH77-MOD2) and the αDEC205:OVA-ORG antibody have very similar targeting capacities for the DEC-
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205 receptor. 60-65% of the total JAWS II CD11c+ DC population were
targeted by the variant αDEC-205:OVA antibodies, whereas 59% of the DC
population was targeted by the αDEC-205:OVA-ORG antibody.

Figure 11. A DC binding assay negative control density plot
showing only JAWS II CD11c+ DCs. There is no positive
staining for the αIgG-FITc antibody, which only targets IgG
molecules.

Figure 12. A DC binding assay positive control density plot
showing JAWS II CD11c+ DCs pulsed with αDEC-205:OVA.
The main population of JAWS II DCs migrate from the initial
“Q3” quadrant to the right as is expected for αIgG-FITc
positively stained DCs.
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Percentage of Antibody Targeted Dendritic
Cells

Dendritic Cell Binding Assay
JAWS II Cells: CD11c+αΙgG-FITC+
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

Figure 13. A dendritic cell binding assay column graph depicting the
percentage of JAWS II CD11c+ αIgG-FITc+ DCs. Flow cytometer data of
the percentage of JAWS II CD11c+ αIgG-FITc+ DCs is taken for each
sample and formatted in a column graph output. All αDEC-205:OVA
antibodies (ORG and variant) showed similar targeting capacities to the
DCs’ DEC-205 receptors.
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In vivo Immunizations
HLA-DR4 mice were immunized with control and modified antibodies
(HC54-MOD1, VH77-MOD1, VH77-MOD2), both with and without a maturation
factor (αCD40) and IFN-γ secretion and antigen-specific T cell expansion were
measured to characterize a pro-inflammatory immune response using an ex
vivo ELISpot assay and a T cell proliferation memory response assay (Tacken
et al. 2007, Hochrein et al. 2001, Letsch et al. 2003).

Ex vivo ELISpot Assay Results
Splenocytes previously immunized with the αDEC-205:OVA-ORG
antibody and agonistic αCD40, after re-stimulation with the OVA class I
peptide (257-264), elicited significant OVA-specific CD8+ T cell immune responses
as defined by IFN-γ secretion. Splenocytes immunized with the αDEC205:OVA-ORG antibody alone secreted significantly less IFN-γ overall with
12.9 spots on average per mouse subject in comparison to 2404.5 spots on
average for mice treated with αDEC-205:OVA-ORG (Mann-Whitney U test
analysis, p-value < 0.0001) (Figure 14). The same result was obtained (p
value ≤ 0.0001) when comparing the IFN-γ responses generated by
splenocytes immunized with the αDEC-205:OVA-ORG antibody + αCD40
condition and splenocytes immunized with the non-specific, non-targeting
αIsotype:OVA + αCD40 condition (Figure 14). Splenocytes from mice
immunized with αDEC-205:OVA-HC54-MOD1, αDEC-205:OVA-VH77-MOD1,
and αDEC-205:OVA-VH77-MOD2 antibodies produced similar levels of IFN-γ
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when re-stimulated with OVA Class I (257-264) (p > 0.05) than the splenocytes
from mice immunized with αDEC-205:OVA-ORG (Figure 15). This suggests
the variant αDEC-205:OVA antibodies, though modified, failed to activate
antigen-specific T cells at greater levels than the αDEC-205:OVA-ORG
immunized splenocytes.
Another experiment was done using the OVA Class II peptide (323-339) to
re-stimulate splenocyte cultures. This peptide tested for OVA specific CD4+ T
cell activation. However, all mice immunization conditions failed to elicit a
memory recall response characterized by IFN-γ secretion, including the
positive control (αDEC-205:OVA antibody + CD40). This result is unexpected
because this peptide is predicted to bind to the HLA-DRB1*0401 allele.
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Spot Forming Cells (1x10^6 cells)
(above bkgrd)

Splenocyte IFN-γ Secretion
OVA (257-264) Class I Re-stimulation
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Figure 14. Splenocyte IFN-γ Secretion: OVA 257-264 Restimulation: Control Plot. This control plot shows
statistically significant elevated IFN-γ responses from
splenocytes immunized with the αDEC-205:OVA +
αCD40 immunization condition than splenocytes
immunized with αDEC-205:OVA-ORG or αISO:OVA +
αCD40 (Mann-Whitney U test; p< 0.0001).
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Figure 15. Splenocyte IFN-γ Secretion: OVA 257-264
Re-stimulation: Experimental Plot. This experimental
plot shows that splenocytes immunized with either
variant αDEC-205:OVA antibodies did not elicit higher
elevated IFN-γ responses than splenocytes
immunized with the non-modified αDEC-205:OVA
immunization condition. (Mann-Whitney U test;
p>0.05).

66

Ex vivo T cell Proliferation Assay
The T cell proliferation assay was performed to test if ovalbuminspecific CD4+ and CD8+ T cell expansion occurred in response to
immunization with the variant antibodies. Significantly more CD4+ and CD8+ T
cell expansion occurred with αDEC-205:OVA antibody combined with the
αCD40 co-stimulatory signal, compared to the weak proliferation levels for
both CD4+ and CD8+ T cell populations when mice were immunized with the
αDEC-205:OVA-ORG antibody alone (Mann-Whitney U test; p<0.0001;
Figures 16,18). Minimal T cell proliferation was observed when the nonspecific, non-targeting control antibody plus maturation factor were used in
immunizations (p-value = 0.003 (CD4), p>0.0001(CD8)) (Figures 16,18).
Immunization of mice with variant antibodies, αDEC-205:OVA-HC54MOD1 and αDEC-205:OVA-VH77-MOD1 did not lead to statistically higher
CD4+ T cell proliferation percentages in splenocytes than splenocytes
immunized with αDEC-205:OVA-ORG (p>0.05; Figure 19). However, mice
immunized with αDEC-205:OVA-VH77-MOD1 (but not αDEC-205:OVA-HC54MOD1) showed significantly higher CD8+ T cell proliferation when compared
to the αDEC-205:OVA-ORG immunization (p<0.05; Figure 17).
Mice immunized with the αDEC-205:OVA-VH77-MOD2 immunization
condition did generate statistically higher CD4+ T cell proliferation percentages
than splenocytes immunized with αDEC-205:OVA-ORG (p<0.05; Figure 19).
However, the αDEC-205:OVA-HC54-MOD1 and αDEC-205:OVA-VH77-MOD2
immunized splenocytes did not elicit statistically significant CD8+ T cell
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proliferation percentages in comparison to splenocytes immunized with αDEC205:OVA-ORG (p>0.05; Figure 17).
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Figure 16. CD8+ T cell Proliferation: Ovalbumin Restimulation Control Plot. This control plot shows
statistically higher and significant CD8+ T cell
proliferation percentages from splenocytes
immunized with the αDEC-205:OVA + αCD40
immunization condition than splenocytes immunized
with αDEC-205:OVA-ORG or αISO:OVA + αCD40
(Mann-Whitney U test; p< 0.0001).
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Figure 17. CD8+ T cell Proliferation: Ovalbumin Restimulation Experimental Plot. This experimental plot
shows statistically higher and significant CD8+ T cell
proliferation percentages from splenocytes
immunized with the αDEC-205:OVA-VH77-MOD1
immunization condition than splenocytes immunized
with αDEC-205:OVA-ORG (Mann-Whitney U test; p<
0.0001). Splenocytes immunized with the αDEC205:OVA-HC54-MOD1 and αDEC-205:OVA-VH77MOD2 did not elicit statistically higher CD8+ T cell
proliferation percentages than splenocytes
immunized with αDEC-205:OVA-ORG (p>0.05).
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Figure 18. CD4+ T cell Proliferation: Ovalbumin Restimulation Control Plot. This control plot shows
statistically higher and significant CD4+ T cell
proliferation percentages from splenocytes immunized
with the αDEC-205:OVA + αCD40 immunization
condition than splenocytes immunized with αDEC205:OVA-ORG or αISO:OVA + αCD40 (Mann-Whitney
U test; p< 0.0001 (ORG), p= 0.003 (ISO:OVA)).
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Figure 19. CD4+ T cell Proliferation: Ovalbumin Restimulation Experimental Plot. This experimental plot
shows statistically higher and significant CD4+ T cell
proliferation percentages from splenocytes immunized
with the αDEC-205:OVA-VH77-MOD2 immunization
condition than splenocytes immunized with αDEC205:OVA-ORG (Mann-Whitney U test; p<0.05).
Splenocytes immunized with the αDEC-205:OVAHC54-MOD1 and αDEC-205:OVA-VH77-MOD1 did
not elicit statistically higher CD4+ T cell proliferation
percentages than splenocytes immunized with αDEC205:OVA-ORG (p>0.05).
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CHAPTER 5

DISCUSSION
Overall, three modified antibodies (αDEC-205:OVA-HC54-MOD1,
αDEC-205:OVA-VH77-MOD1, αDEC-205:OVA-VH77-MOD2) were
successfully expressed and administered in in vivo immunizations to HLA-DR4
mice. Data from the in vivo immunizations indicated that statistically higher T
cell proliferation was observed from splenocytes immunized with αDEC205:OVA-VH77-MOD1 (CD8+ T cells) and αDEC-205:OVA-VH77-MOD2
(CD4+ T cells) than splenocytes immunized with the non-modified αDEC205:OVA-ORG immunization condition. However, the data indicated that there
was not a statistically elevated IFN-γ response from the splenocytes
immunized with any of the three variant αDEC-205:OVA antibodies in
comparison to the non-modified αDEC-205:OVA-ORG immunized
splenocytes. No statistically significant elevated responses characteristic of an
effector immune response was reported for splenocytes immunized with the
αDEC-205:OVA-HC54-MOD1 immunization condition. Overall, this data
suggests that the modifications to the potential VH77 Tregitope sequence lead
to a decrease in antibody tolerogenicity and resulted in a potentially novel and
increased immunogenic vaccine antigen delivery vehicle.
Our results that the αDEC-205:OVA monoclonal antibody is an effective
delivery vehicle selectively targeting APCs for ovalbumin-antigen presentation
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to CD4+ and CD8+ T cells confirmed previous findings presented by Bonifaz et
al. 2004 and Tacken et al. 2007. Generally, antigen targeted to the DEC-205
receptor is trafficked to the MHC II presentation pathway where MHC II
molecules present antigenic peptides to CD4+ T cells specifically. This work
provides evidence that when the αDEC-205:OVA-VH77-MOD2 antibody
targets the DEC-205 receptor, the receptor’s bias towards CD4+ T cells is
showcased, which is due to the proximal and distal regions of the DEC-205
receptor’s cytosolic tail, which targets late endosomal vesicles containing MHC
II molecules (Figure 19) (Tacken et al. 2007, Steinman et al. 2000, Lahoud et
al. 2012, Mahnke et al. 2000, Harding et al. 2010) This work also provides
further evidence, initially reported by Bonifaz et al. 2004, that though the DEC205 receptor is biased towards the MHC II pathway, that targeting the DEC205 receptor can also traffic antigen to MHC I molecules for CD8+ T cell
presentation, in which our results show the use of αDEC-205:OVA-VH77MOD1 during in vivo immunizations results in CD8+ T cell proliferation after
splenocytes have been re-stimulated with either OVA (257-264) or ovalbumin
(Figures 14-17). Due to the occurrence of CD8+ T cell proliferation in our
results, this suggests that cross presentation is occurring, which is the process
in which antigenic peptides make their way out into the cytosol for proteasomal
degradation and are then taken back into the lumen of the Endoplasmic
Reticulum for peptide loading onto MHC I molecules and take part in the MHC
I pathway (Steinman et al. 2000, Janeway et al. 2001).
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We found that immunization of mice with antibodies in which
modifications to the VH77 Tregitope sequence, located in the variable region
of the heavy chain (Table 10) (αDEC-205:OVA-VH77-MOD1 and αDEC205:OVA-VH77-MOD2), led to significantly higher levels of CD8+ and CD4+ T
cell proliferation (respectively) than mice immunized with the antibody
containing unmodified Tregitopes, suggesting that the point mutations lowered
the tolerogenicity level of the antibody and increased the antibody’s
immunogenicity allowing for a potential effector immune response,
characterized by T cell proliferation and IFN-γ secretion, to ensue. This further
suggests that the potential Tregitope effect was fully knocked out and allowed
for the proverbial “immunological balance” with tolerance on one arm of the
scale and immunogenicity on the other, to shift towards immunogenicity.
Therefore, enabling the αDEC-205:OVA-VH77-MOD1 or αDEC-205:OVAVH77-MOD2 targeting antibodies to induce a potential pro-inflammatory
immune response without the need for a maturation factor or co-stimulatory
molecule (Moise et al. 2012, De Groot et al. 2008).
However, the modified antibodies (VH77-MOD1 and VH77-MOD2)
immunized splenocytes did not induce statistically elevated IFN-γ responses.
Overall, an elevated IFN-γ response per se was not expected to occur.
Though IFN-γ does not need to be seen at elevated levels to indicate an
immune response, it could still be seen as an indicator that further cytokine
presence should be analyzed to determine if there is a cytokine during
antigen-re-stimulation that is prevalent above all other cytokines. For instance,
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cytokines such as IL-2, IL-4, IL-12, and TNF-α or IL-10, and TGF-β could be
reviewed in culture supernatants to identify the type of immune response that
is being induced by these variant antibodies during ex vivo culture and restimulation of splenocytes (Steinman et al 2000, De Groot et al. 2008,
Cousens et al. 2013).
Splenocytes from all of the immunized conditions were treated to not
only OVA (257-264), but also OVA (323-339) during the ELISpot assay; however, the
splenocytes treated with OVA (323-339) failed to become activated and thus did
not secrete IFN-γ. OVA (323-339) is a class II peptide (Table 4) that can be found
within ovalbumin, the whole protein, that was conjugated to the αDEC-205
antibody and administered to the DR4 mice during in vivo immunizations.
Thus, if the ovalbumin had been processed and degraded into peptides by the
acid proteases (Cathepsins S & L) within the acidic endosomal/lysosomal
vesicles, then it is possible that OVA (323-339) could have been generated
through this degradation process. Then OVA (323-339) would be presented by
MHC molecules to circulating T cells for the subsequent activation and
induction of a protective immune response. Some of the potential effector T
cells generated from the initial immune response then differentiate into
memory T cells. Memory T cells, upon recognition of the same OVA (323-339)
antigen, are then able to rapidly turn into effector T cells once again and
induce an accelerated antigen-specific T cell mediated immune response.
However, because IFN-γ was not secreted after re-stimulation with OVA (323-
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339) that

suggests that the initial breakdown of ovalbumin into peptides during

in vivo immunizations did not generate OVA (323-339) for presentation to T cells.
Since CD4+ T cell proliferation was observed in the T cell proliferation
assay, this means that class II peptides can be presented to T cells and T cells
are able to subsequently recognize the peptide, bind to the complex, and
initiate proliferation. This result is suggesting that there are potentially other
class II peptides within ovalbumin that can be presented to T cells and induce
an immune response. This is definitely possible because the initial in silico
prediction of OVA (323-339) binding potential was 1.66. A score of 1.64 or greater
is required for any sequence frame to have a significant chance of binding to a
given HLA allele. Thus, because the OVA (323-339) sequence had an EpiMatrix
z-score of 1.66, it is considered a top 5% hit, but it is on the EpiMatrix z-score
significance level threshold, which suggests there is potential for this
sequence to be a false positive binder to the DR4 allele. An HLA-DR4 binding
assay that would test the strength of the OVA (323-339) binding potential to the
DR4 allele would be required to confirm a false positive binding theory.
Furthermore, because of the possibility for OVA (323-339) to be a false positive
binder to the DR4 allele, it is therefore possible that even if the sequence was
generated during proteolytic processing of ovalbumin, an immune response
would not be generated. An additional issue to consider as to why a lack of
immune response was generated after OVA (323-339) was assayed is that the
working stock solution that was used potentially could have been unstable and
degraded. Generally, this can occur due to repeated “freeze-thaw cycles”,
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which can also lead to loss of stability (Nowatzke et al. 2003). However,
measures were taken prior to peptide usage in immunogenicity assays to
counteract such instances, such as aliquoting the solvated peptide in usable
volumes.
As for the αDEC-205:OVA-HC54-MOD1 immunization condition, no
statistically elevated levels of T cell proliferation or IFN-γ secretion was
observed. Splenocytes immunized with this particular variant antibody
generated data similar to the αDEC-205:OVA-ORG immunization condition.
This variant antibody was generated by modifying the constant heavy chain
region and is not associated with the variable heavy chain (VH77) Tregitope
sequence (Figure 7). Possible reasons why pro-inflammatory immune
response characteristics were not observed for the αDEC-205:OVA-HC54MOD1 immunization condition at statistically elevated levels in comparison to
the non-modified αDEC-205:OVA-ORG immunization condition are that it may
not be the most tolerogenic Tregitope sequence or it may not have been fully
deleted for an effector (pro-inflammatory) immune response to take hold.
Unpublished reports (from De Groot et al.) indicate the human Tregitope
sequence (Hu84) (mouse equivalent to VH77) is the most tolerogenic out of
the three potential Tregitope sequences (Hu84, Hu167, Hu289). Therefore, if a
pro-inflammatory immune response were to occur, it would have been
expected when the αDEC-205:OVA-VH77 (MOD1 and MOD2) antibodies
were used in immunizations, due to modifications to the VH77 Tregitope
sequence, which is what we observed in T cell proliferation measurements.
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However, published reports from De Groot et al. 2008 identified two other
strong epitope clusters, Hu167 and Hu289. The same EpiMatrix suite of in
silico tools used in this research project were used to identify these potential
tolerogenic T cell epitopes, which showcased EpiBars (band-like patterns) or
dense populations of epitope hits against a panel of eight class II alleles
representative of highly promiscuous and potentially immunodominant
epitopes that showed homology to human immunoglobulin. These T cell
epitope sequences were found to rank highly on the human immunogenicity
scale (De Groot et al. 2008, Cousens et al. 2013).
De Groot et al. 2008 demonstrated the effectiveness of the human
Tregitope sequence Hu167, homologous to murine Tregitope sequence HC54,
to induce a 2-fold increase in CD4+CD25+FoxP3+ T cells after Tregitope
stimulation (including Hu289) to PBMCs, which had suggested the activation
of Tregs and confirmed the expected activity of Tregitopes. Further, studies
performed by Cousens et al. 2013 using the murine Tregitope equivalents to
human Tregitopes Hu167 and Hu289 showed similar T regulatory cell
activation and effector immune response suppression in non-obese diabetic
mice (NOD). Furthermore, Tregitope activity with the co-administration of Type
1 diabetes antigen was shown to delay the onset of hyperglycemia and reduce
the incidence rate in non-obese diabetic mice (NOD), as well as suppress the
effects of diabetes after development in NOD mice (Cousens et al. 2013).
Previous research has demonstrated that these Tregitope sequences
can generate Treg cells. Modifications to the single HC54 epitope sequence
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tested here may not have been enough to overcome the tolerogenicity level of
an antibody containing the other two potential highly tolerogenic Tregitope
sequences (Hu84 (mouse VH77) and Hu289). Further evidence that more
extensive modification is required, when the “highest” tolerogenic Tregitope
sequence is not targeted for modification, is the presence of potential
regulatory sequence frames. Even after modifications, the αDEC-205:OVAHC54-MOD1 antibody retained one sequence frame predicted to have a
significant chance of binding to the HLA-DR4 allele. De Groot et al. previously
demonstrated the effectiveness of the human and murine Tregitope
sequences to induce Treg cells with Tregitope stimulation; therefore, it is
possible with one sequence frame still predicted to bind to the DR4 allele in
the HC54 Tregitope sequence, that the full Tregitope effect has not been
knocked out and if the sequence is presented it could activate Tregs (De Groot
et al. 2008, De Groot et al. 2013). An HLA-DR4 binding assay could be
performed to confirm whether the Tregitope sequences are positive binders,
which could suggest the potential likelihood for Tregitope presentation and
Treg cell activation.
Overall, this study provided data that suggests modifying specific
Tregitope sequences within the αDEC-205:OVA antibody is capable of
rendering the antibody less tolerogenic, allowing for the induction of
statistically significant levels of pro-inflammatory immune responses after
antigen re-stimulation. Consequently, the information provided by this study
could add to the vaccination strategy repertoire and become a viable option to
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consider when utilizing therapeutic antibodies as a means for immunotherapy
in regards to autoimmunity, tumors, and potentially HIV and cancer. However,
the big issue plaguing most therapeutic antibodies is the immune response
generated by the antibody and associated biologic proteins that can interfere
with treatment efficacy due to anti-drug antibodies (De Groot et al. 2013).
Therefore, it would be necessary to confirm the immunogenicity of the
antibody first prior to use in clinical studies. However, this potentially improved
vaccine delivery platform system may be most efficient as a vaccination
strategy prior to infection since immunity against specific pathogens could be
garnered by coupling specific antigens to the targeted therapeutic antibody to
generate immune system recognition and lead to memory.
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CHAPTER 6

CONCLUSION
By harnessing the innate ability of the DEC-205 receptor, found
ubiquitously on DCs, to ingest pathogen, process it, and present its antigenic
peptides to T cells, it has become a viable candidate for novel targeted
vaccination strategies. The overall goal of this study was to create an
improved vaccine delivery system by modifying regulatory T cell epitopes
found within the αDEC-205:OVA antibody’s sequence. These modifications
would in turn generate newly de-tolerized monoclonal antibodies capable of
targeting the DEC-205 receptor and serve as delivery vehicles for vaccine test
antigens to raise a robust antigen-specific T cell mediated protective immune
responses.
Two monoclonal antibodies stood out amongst the three total variant
antibody sequences, the αDEC-205:OVA-VH77-MOD1 and αDEC205:OVAVH77-MOD2 antibody. The αDEC-205:OVA-VH77-MOD1 retained
one predicted and potential regulatory sequence frame predicted to bind to the
DR4 allele, while the αDEC-205:OVA-VH77-MOD2 antibody did not retain any
potential regulatory sequence frames predicted to bind. However, when both
antibody sequences (VH77-MOD1 and VH77-MOD2) were administered in in
vivo immunizations, without co-stimulatory factors, CD8+ and CD4+ T cell
proliferation was induced, respectively. These results were statistically
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significant when compared to the baseline levels of the non-modified αDEC205:OVA-ORG antibody immunized splenocytes.
An improved novel targeted vaccination strategy, raising antigenspecific immune responses, is underway and the successful first steps have
been taken. The next steps to take would be to perform studies that further
establish what types of T cells are proliferating. These studies have given
initial estimates that the T cells that are proliferating are potentially effector in
nature due to IFN-γ secretion; however, further application of splenocytes in T
cell proliferation and phenotyping assays, from more in vivo immunizations,
will assess if the T cells present and proliferating are effector or regulatory in
nature due to the application of intracellular staining. Intracellular staining can
confirm the T cell phenotype established by extracellular staining based on the
identification of transcription factors, present after antigen re-stimulation,
associated with either effector or regulatory immune responses.
It would be interesting to see whether levels of Treg expression
increased when comparing all four antibodies (ORG and three variants)
against one another. Higher Treg expression would be expected with the
αDEC-205:OVA-ORG (no Tregitope modification) and αDEC-205:OVA-HC54MOD1 (no statistically significant data) conditions. Whereas, Treg cell levels
would be expected to decrease when the αDEC-205:OVA-VH77-MOD1 and
αDEC-205:OVA-VH77-MOD2 conditions are used and subsequent T cell
proliferation is phenotyped.
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Also, further site directed mutagenesis work could be performed to the
αDEC-205:OVA-VH77-MOD2 antibody. This process would be performed
again to determine if further modification to additional Tregitope sequences to
αDEC-205:OVA-VH77-MOD2 antibody imparted further reduction in tolerance
and increased expression of pro-inflammatory immune responses.
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